<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "ich-icsr-v2.1.dtd">
<ichicsr lang="en">
  <ichicsrmessageheader>
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>1.0</messageformatrelease>
    <messagenumb>2022-04</messagenumb>
    <messagesenderidentifier>FDA CDER</messagesenderidentifier>
    <messagereceiveridentifier>Public Use</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20220424074800</messagedate>
  </ichicsrmessageheader>
  <safetyreport>
    <safetyreportversion>3</safetyreportversion>
    <safetyreportid>19454107</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220425</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20210623</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220104</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-KYOWAKIRIN-2021BKK010344</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Constipation</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Decreased appetite</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>NOURIANZ</medicinalproduct>
        <drugbatchnumb>CDNCX</drugbatchnumb>
        <drugauthorizationnumb>22075</drugauthorizationnumb>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>20 MG, ONE TABLET ONCE DAILY</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Parkinson^s disease</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20201113</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>ISTRADEFYLLINE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20270107</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220425</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>1</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220101</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220101</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0256501</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Overdose</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DILAUDID</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>HYDROMORPHONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MS CONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MORPHINE SULFATE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20300948</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>1</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220105</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220105</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0252288</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Overdose</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DILAUDID</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>HYDROMORPHONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MS CONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MORPHINE SULFATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DEMEROL</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MEPERIDINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>5</safetyreportversion>
    <safetyreportid>19264942</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20210517</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220131</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>NVSC2021US108270</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Arthralgia</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>COSENTYX</medicinalproduct>
        <drugbatchnumb>not available</drugbatchnumb>
        <drugauthorizationnumb>125504</drugauthorizationnumb>
        <drugstructuredosagenumb>300</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>802</drugintervaldosagedefinition>
        <drugdosagetext>UNK UNK, QW</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Psoriatic arthropathy</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210504</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>SECUKINUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>COSENTYX</medicinalproduct>
        <drugauthorizationnumb>125504</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>SECUKINUMAB</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20395365</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220130</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220130</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-NOVARTISPH-NVSC2022US020023</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>41</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Colorectal cancer</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Incorrect dose administered</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugauthorizationnumb>74467</drugauthorizationnumb>
        <drugstructuredosagenumb>150</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>25 MG,75 MG,150 MG,,DAILY,</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201001</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201512</drugenddate>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugauthorizationnumb>74467</drugauthorizationnumb>
        <drugdosageform>Tablet</drugdosageform>
        <drugindication>Dyspepsia</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugauthorizationnumb>74467</drugauthorizationnumb>
        <drugdosageform>Tablet</drugdosageform>
        <drugindication>Gastrooesophageal reflux disease</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugstructuredosagenumb>150</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>25 MG,75 MG,150 MG,,DAILY,</drugdosagetext>
        <drugdosageform>Capsule, hard</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201001</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201512</drugenddate>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugdosageform>Capsule, hard</drugdosageform>
        <drugindication>Dyspepsia</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugdosageform>Capsule, hard</drugdosageform>
        <drugindication>Gastrooesophageal reflux disease</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20150101</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20345305</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220118</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220118</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-CELGENE-USA-20220103809</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>Optum Specialty Pharmacy</duplicatesource>
      <duplicatenumb>AE00542964</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>2</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>80</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Nasopharyngitis</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugauthorizationnumb>021880</drugauthorizationnumb>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>10 MILLIGRAM</drugdosagetext>
        <drugdosageform>Capsules</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Plasma cell myeloma</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202103</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20220112</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20368848</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedate>20220121</receivedate>
    <receiptdate>20220121</receiptdate>
    <fulfillexpeditecriteria>3</fulfillexpeditecriteria>
    <authoritynumb>FDA-CDER-CTU-2022-5908</authoritynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>57</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>117.03</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Nasopharyngitis</reactionmeddrapt>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HUMIRA</medicinalproduct>
        <drugbatchnumb>1155481</drugbatchnumb>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>2</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>FREQUENCY : EVERY OTHER WEEK;?</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Rheumatoid arthritis</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202101</drugstartdate>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ADALIMUMAB</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20283569</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220103</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220103</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0268078</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Overdose</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MS CONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MORPHINE SULFATE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20386148</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220127</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220127</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-NOVARTISPH-NVSC2022US016187</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Cerebrovascular accident</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>VOLTAREN</medicinalproduct>
        <drugauthorizationnumb>21005</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Gel</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>DICLOFENAC SODIUM</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>19921660</safetyreportid>
    <primarysourcecountry>CA</primarysourcecountry>
    <occurcountry>CA</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>3</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211006</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220128</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>CA-TOLMAR, INC.-21CA028490</companynumb>
    <primarysource>
      <reportercountry>CA</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Hot flush</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ELIGARD</medicinalproduct>
        <drugauthorizationnumb>021488</drugauthorizationnumb>
        <drugstructuredosagenumb>30</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>4</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>802</drugintervaldosagedefinition>
        <drugdosagetext>30 MILLIGRAM, Q 4 MONTH</drugdosagetext>
        <drugdosageform>Subcutaneous injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Prostate cancer</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20091014</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>LEUPROLIDE ACETATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ELIGARD</medicinalproduct>
        <drugbatchnumb>11813A; 11812A; UNK</drugbatchnumb>
        <drugauthorizationnumb>021488</drugauthorizationnumb>
        <drugstructuredosagenumb>30</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>4</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>802</drugintervaldosagedefinition>
        <drugdosagetext>30 MILLIGRAM, Q 4 MONTH</drugdosagetext>
        <drugdosageform>Subcutaneous injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210625</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>LEUPROLIDE ACETATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ELIGARD</medicinalproduct>
        <drugbatchnumb>11895A; 12150A; UNK</drugbatchnumb>
        <drugauthorizationnumb>021488</drugauthorizationnumb>
        <drugstructuredosagenumb>30</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>4</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>802</drugintervaldosagedefinition>
        <drugdosagetext>30 MILLIGRAM, Q 4 MONTH</drugdosagetext>
        <drugdosageform>Subcutaneous injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211016</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>LEUPROLIDE ACETATE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20341133</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220117</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220117</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-UCBSA-2022000754</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>83</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Death</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CERTOLIZUMAB PEGOL</medicinalproduct>
        <drugstructuredosagenumb>400</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>4</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>400 MILLIGRAM, EV 4 WEEKS</drugdosagetext>
        <drugdosageform>Powder and solvent for solution for injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Rheumatoid arthritis</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>CERTOLIZUMAB PEGOL</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211123</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20369570</safetyreportid>
    <primarysourcecountry>GB</primarysourcecountry>
    <occurcountry>GB</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220124</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220124</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <authoritynumb>GB-MHRA-EYC 00271572</authoritynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>MHRA</duplicatesource>
      <duplicatenumb>GB-MHRA-ADR 26486914</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>GB</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>85</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientagegroup>6</patientagegroup>
      <patientweight>54</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Hypertensive crisis</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MEMANTINE</medicinalproduct>
        <drugauthorizationnumb>200155</drugauthorizationnumb>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>5 MG OD</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Dementia</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20220117</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20220118</drugenddate>
        <drugtreatmentduration>1</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>MEMANTINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ATORVASTATIN</medicinalproduct>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugindication>Ill-defined disorder</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ATORVASTATIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>DIGOXIN</medicinalproduct>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugindication>Ill-defined disorder</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>DIGOXIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>EPLERENONE</medicinalproduct>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugindication>Ill-defined disorder</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>EPLERENONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FOLIC ACID</medicinalproduct>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugindication>Ill-defined disorder</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>FOLIC ACID</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ISOSORBIDE MONONITRATE</medicinalproduct>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugindication>Ill-defined disorder</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ISOSORBIDE MONONITRATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ACETAMINOPHEN</medicinalproduct>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugindication>Ill-defined disorder</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ACETAMINOPHEN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>XARELTO</medicinalproduct>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugindication>Ill-defined disorder</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RIVAROXABAN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>MINERAL OIL\PARAFFIN</medicinalproduct>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugindication>Ill-defined disorder</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MINERAL OIL\PARAFFIN</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20220117</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20363602</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220121</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220121</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-144755</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Product contamination physical</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Staphylococcal infection</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>KENALOG</medicinalproduct>
        <drugbatchnumb>ABF3576</drugbatchnumb>
        <drugauthorizationnumb>012041</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>TRIAMCINOLONE ACETONIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20394737</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220130</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220130</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-ELI_LILLY_AND_COMPANY-US202201010988</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>48</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Retinal vascular disorder</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Injection site haemorrhage</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HUMALOG MIX75/25</medicinalproduct>
        <drugbatchnumb>D211432F</drugbatchnumb>
        <drugauthorizationnumb>021017</drugauthorizationnumb>
        <drugdosagetext>UNK UNK, UNKNOWN</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202107</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>INSULIN LISPRO</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20210701</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20365347</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220122</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220122</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-JNJFOC-20220132511</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>26</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientagegroup>5</patientagegroup>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Fatigue</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Abdominal pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>STELARA</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugauthorizationnumb>125261</drugauthorizationnumb>
        <drugstructuredosagenumb>90</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosageform>Solution for injection in pre-filled syringe</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210118</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>USTEKINUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>STELARA</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugauthorizationnumb>125261</drugauthorizationnumb>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>USTEKINUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211229</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20333516</safetyreportid>
    <primarysourcecountry>FR</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220113</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220113</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>FR-Merck Healthcare KGaA-9281328</companynumb>
    <primarysource>
      <reportercountry>FR</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Suicidal ideation</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LEVOTHYROXINE</medicinalproduct>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>LEVOTHYROXINE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20353623</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>3</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220120</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220120</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-NEUROCRINE BIOSCIENCES INC.-2022NBI00250</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Nasopharyngitis</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>INGREZZA</medicinalproduct>
        <drugbatchnumb>2100123</drugbatchnumb>
        <drugauthorizationnumb>209241</drugauthorizationnumb>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>40 MILLIGRAM, QD</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Tardive dyskinesia</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210122</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>VALBENAZINE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20290687</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220104</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220104</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-GALDERMA-US2021020195</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Acne</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug ineffective</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PROACTIV MD ADAPALENE ACNE TREATMENT</medicinalproduct>
        <drugbatchnumb>S1030A</drugbatchnumb>
        <drugauthorizationnumb>20380</drugauthorizationnumb>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>1 DOSAGE FORM, QD, AT NIGHT</drugdosagetext>
        <drugdosageform>Gel</drugdosageform>
        <drugadministrationroute>061</drugadministrationroute>
        <drugindication>Acne</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202110</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>202112</drugenddate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>ADAPALENE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Proactiv MD Ultra Gentle Cleanser</medicinalproduct>
        <drugbatchnumb>S1054B</drugbatchnumb>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>1 DOSAGE FORM, BID, MORNING AND NIGHT</drugdosagetext>
        <drugdosageform>Cutaneous solution</drugdosageform>
        <drugadministrationroute>061</drugadministrationroute>
        <drugindication>Acne</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202110</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>202112</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Proactiv MD Ultra Hydrating Moisturizer</medicinalproduct>
        <drugbatchnumb>VR1036B</drugbatchnumb>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>1 DOSAGE FORM, BID, MORNING AND NIGHT</drugdosagetext>
        <drugdosageform>Cutaneous solution</drugdosageform>
        <drugadministrationroute>061</drugadministrationroute>
        <drugindication>Acne</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202110</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>202112</drugenddate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Proactiv Amazonian Clay Mask</medicinalproduct>
        <drugbatchnumb>V1166A</drugbatchnumb>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>1 DOSAGE FORM, BID, MORNING AND NIGHT</drugdosagetext>
        <drugdosageform>Cutaneous paste</drugdosageform>
        <drugadministrationroute>061</drugadministrationroute>
        <drugindication>Acne</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202110</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>202112</drugenddate>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211101</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>4</safetyreportversion>
    <safetyreportid>20081365</safetyreportid>
    <primarysourcecountry>CA</primarysourcecountry>
    <occurcountry>CA</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211117</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220106</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>CA-PFIZER INC-2020483805</companynumb>
    <primarysource>
      <reportercountry>CA</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>78</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>51</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Blindness</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Inappropriate schedule of product administration</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Off label use</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Intentional product use issue</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Stress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RUXIENCE</medicinalproduct>
        <drugauthorizationnumb>761103</drugauthorizationnumb>
        <drugstructuredosagenumb>1000</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>1000 MG, DAY 1 AND DAY 15</drugdosagetext>
        <drugdosageform>Solution for infusion</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>Rheumatoid arthritis</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20201106</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>RITUXIMAB-PVVR</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RUXIENCE</medicinalproduct>
        <drugbatchnumb>DR3131</drugbatchnumb>
        <drugauthorizationnumb>761103</drugauthorizationnumb>
        <drugstructuredosagenumb>1000</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>1000 MG, DAY 1 AND DAY 15</drugdosagetext>
        <drugdosageform>Solution for infusion</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20201204</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>RITUXIMAB-PVVR</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RUXIENCE</medicinalproduct>
        <drugauthorizationnumb>761103</drugauthorizationnumb>
        <drugstructuredosagenumb>1000</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>1000 MG, DAY 1 AND DAY 15</drugdosagetext>
        <drugdosageform>Solution for infusion</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210512</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>RITUXIMAB-PVVR</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RUXIENCE</medicinalproduct>
        <drugbatchnumb>EG4735</drugbatchnumb>
        <drugauthorizationnumb>761103</drugauthorizationnumb>
        <drugstructuredosagenumb>1000</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>1000 MG, DAY 1 AND DAY 15</drugdosagetext>
        <drugdosageform>Solution for infusion</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210527</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>RITUXIMAB-PVVR</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RUXIENCE</medicinalproduct>
        <drugbatchnumb>EK7979</drugbatchnumb>
        <drugauthorizationnumb>761103</drugauthorizationnumb>
        <drugstructuredosagenumb>1000</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>1000MG, DAY 1 AND DAY 15</drugdosagetext>
        <drugdosageform>Solution for infusion</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211119</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>RITUXIMAB-PVVR</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ESCITALOPRAM</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <activesubstance>
          <activesubstancename>ESCITALOPRAM OXALATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>HYDROCHLOROTHIAZIDE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <activesubstance>
          <activesubstancename>HYDROCHLOROTHIAZIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PRINIVIL</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>1 DF DOSAGE INFORMATION NOT AVAILABLE</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <activesubstance>
          <activesubstancename>LISINOPRIL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>RABEPRAZOLE</medicinalproduct>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>20 MG</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <activesubstance>
          <activesubstancename>RABEPRAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20201204</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>20078258</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211117</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220121</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-LUPIN PHARMACEUTICALS INC.-2021-22437</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Device delivery system issue</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>No adverse event</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ALBUTEROL SULFATE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>209954</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Inhalation solution</drugdosageform>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ALBUTEROL SULFATE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20337403</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220114</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220114</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-SA-SAC20220106000837</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>SA</duplicatesource>
      <duplicatenumb>US-SA-SAC20220106000837</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>ARTEMIS</duplicatesource>
      <duplicatenumb>SAC20220106000837</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>PORTAL ID</duplicatesource>
      <duplicatenumb>SanofiPVPortal20220106000279</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientagegroup>5</patientagegroup>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Clumsiness</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Fall</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>AUBAGIO</medicinalproduct>
        <drugauthorizationnumb>202992</drugauthorizationnumb>
        <drugstructuredosagenumb>14</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>14 MG, QD</drugdosagetext>
        <drugdosageform>Coated tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Multiple sclerosis</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20190927</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>TERIFLUNOMIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>20221570</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211223</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220113</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-LUPIN PHARMACEUTICALS INC.-2021-24835</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
      <literaturereference>Naeem F, Vijayan V, Kim BY, Rahmati E, McCarty J. Congenital Coccidioidomycosis: A Case Report and Review of the Literature. Journal of the Pediatric Infectious Diseases Society. 2021;10(7):789-792</literaturereference>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientagegroup>2</patientagegroup>
      <patientweight>1.015</patientweight>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Premature baby</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Low birth weight baby</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Neonatal respiratory distress</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Coccidioidomycosis</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Neonatal respiratory distress syndrome</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Hyperbilirubinaemia neonatal</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Feeding disorder</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Foetal exposure during pregnancy</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BETAMETHASONE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>209106</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>064</drugadministrationroute>
        <drugindication>Maternal therapy to enhance foetal lung maturity</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>BETAMETHASONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>AMPHOTERICIN B</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>064</drugadministrationroute>
        <drugindication>Coccidioidomycosis</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>AMPHOTERICIN B</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>4</safetyreportversion>
    <safetyreportid>20084396</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211118</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220127</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-AMGEN-USASP2021178517</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>AMGEN INC</duplicatesource>
      <duplicatenumb>US-AMGEN INC-21-0310908-SR-01</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>44</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientagegroup>5</patientagegroup>
      <patientweight>81.633</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Intercepted product preparation error</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>NEULASTA</medicinalproduct>
        <drugbatchnumb>1133309A</drugbatchnumb>
        <drugauthorizationnumb>125031</drugauthorizationnumb>
        <drugstructuredosagenumb>6</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>6 MILLIGRAM</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Neutropenia</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>PEGFILGRASTIM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>NEULASTA</medicinalproduct>
        <drugbatchnumb>0010559352</drugbatchnumb>
        <drugauthorizationnumb>125031</drugauthorizationnumb>
        <drugstructuredosagenumb>6</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>6 MILLIGRAM</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>PEGFILGRASTIM</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211110</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20379249</safetyreportid>
    <primarysourcecountry>IN</primarysourcecountry>
    <occurcountry>IN</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220126</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220126</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>IN-BAYER-2022A011905</companynumb>
    <primarysource>
      <reportercountry>IN</reportercountry>
      <qualification>3</qualification>
      <literaturereference>Goel R; Panaiyadiyan S; Nayak B; Singh P. Multimodal management of locally advanced rhabdoid tumour of the kidney in an adult. BMJ Case Reports. 2021;14:4:e236830</literaturereference>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>65</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientagegroup>6</patientagegroup>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Rhabdoid tumour of the kidney</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Metastases to spleen</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Metastases to pancreas</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Off label use</reactionmeddrapt>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SORAFENIB</medicinalproduct>
        <drugauthorizationnumb>021923</drugauthorizationnumb>
        <drugstructuredosagenumb>400</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>400 MG, BID</drugdosagetext>
        <drugdosageform>Film-coated tablet</drugdosageform>
        <drugindication>Rhabdoid tumour of the kidney</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>SORAFENIB</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20368165</safetyreportid>
    <primarysourcecountry>FR</primarysourcecountry>
    <occurcountry>FR</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220124</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220124</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>FR-TAKEDA-2022TUS002370</companynumb>
    <primarysource>
      <reportercountry>FR</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>64</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Chronic kidney disease</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TEDUGLUTIDE</medicinalproduct>
        <drugauthorizationnumb>203441</drugauthorizationnumb>
        <drugstructuredosagenumb>2.35</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>2.35 MILLIGRAM, 1/WEEK</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Short-bowel syndrome</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20191022</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20210318</drugenddate>
        <drugtreatmentduration>514</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>2</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>TEDUGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TEDUGLUTIDE</medicinalproduct>
        <drugauthorizationnumb>203441</drugauthorizationnumb>
        <drugstructuredosagenumb>2.35</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>2.35 MILLIGRAM, 1/WEEK</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Short-bowel syndrome</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20191022</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20210318</drugenddate>
        <drugtreatmentduration>514</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>2</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>TEDUGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TEDUGLUTIDE</medicinalproduct>
        <drugauthorizationnumb>203441</drugauthorizationnumb>
        <drugstructuredosagenumb>2.35</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>2.35 MILLIGRAM, 1/WEEK</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Short-bowel syndrome</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20191022</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20210318</drugenddate>
        <drugtreatmentduration>514</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>2</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>TEDUGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TEDUGLUTIDE</medicinalproduct>
        <drugauthorizationnumb>203441</drugauthorizationnumb>
        <drugstructuredosagenumb>2.35</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>2.35 MILLIGRAM, 1/WEEK</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Short-bowel syndrome</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20191022</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20210318</drugenddate>
        <drugtreatmentduration>514</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>2</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>TEDUGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TEDUGLUTIDE</medicinalproduct>
        <drugauthorizationnumb>203441</drugauthorizationnumb>
        <drugstructuredosagenumb>1.25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>1.25 MILLIGRAM, 1/WEEK</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210319</drugstartdate>
        <actiondrug>2</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>TEDUGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TEDUGLUTIDE</medicinalproduct>
        <drugauthorizationnumb>203441</drugauthorizationnumb>
        <drugstructuredosagenumb>1.25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>1.25 MILLIGRAM, 1/WEEK</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210319</drugstartdate>
        <actiondrug>2</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>TEDUGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TEDUGLUTIDE</medicinalproduct>
        <drugauthorizationnumb>203441</drugauthorizationnumb>
        <drugstructuredosagenumb>1.25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>1.25 MILLIGRAM, 1/WEEK</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210319</drugstartdate>
        <actiondrug>2</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>TEDUGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TEDUGLUTIDE</medicinalproduct>
        <drugauthorizationnumb>203441</drugauthorizationnumb>
        <drugstructuredosagenumb>1.25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>1.25 MILLIGRAM, 1/WEEK</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210319</drugstartdate>
        <actiondrug>2</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>TEDUGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ARIXTRA</medicinalproduct>
        <drugstructuredosagenumb>7.5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>7.50 MILLIGRAM, QD</drugdosagetext>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Venous thrombosis</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20201116</drugstartdate>
        <activesubstance>
          <activesubstancename>FONDAPARINUX SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LOPERAMIDE</medicinalproduct>
        <drugstructuredosagenumb>2</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>4</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>2 DOSAGE FORM, QID</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Short-bowel syndrome</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2017</drugstartdate>
        <activesubstance>
          <activesubstancename>LOPERAMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CALCIUM</medicinalproduct>
        <drugstructuredosagenumb>1000</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1000 MILLIGRAM, QD</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Malabsorption</drugindication>
        <activesubstance>
          <activesubstancename>CALCIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LANSOPRAZOLE</medicinalproduct>
        <drugstructuredosagenumb>30</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>30 MILLIGRAM, QD</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Short-bowel syndrome</drugindication>
        <activesubstance>
          <activesubstancename>LANSOPRAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20210201</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20312932</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220108</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220108</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0280914</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientagegroup>1</patientagegroup>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Foetal exposure during pregnancy</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome neonatal</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>064</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20283469</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>1</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220103</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220103</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0267842</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Overdose</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20407607</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220131</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220131</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-BIOMARINAP-US-2022-141078</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientagegroup>5</patientagegroup>
      <patientweight>71.3</patientweight>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Arthralgia</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PALYNZIQ</medicinalproduct>
        <drugbatchnumb>unknown</drugbatchnumb>
        <drugauthorizationnumb>761079</drugauthorizationnumb>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>10 MILLIGRAM, QD</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Phenylketonuria</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PEGVALIASE-PQPZ</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PALYNZIQ</medicinalproduct>
        <drugbatchnumb>not reported</drugbatchnumb>
        <drugauthorizationnumb>761079</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210921</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PEGVALIASE-PQPZ</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FAMOTIDINE</medicinalproduct>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>20 MILLIGRAM, BID</drugdosagetext>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>FAMOTIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CLARITIN</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>10 MILLIGRAM, QD</drugdosagetext>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>LORATADINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TRINESSA</medicinalproduct>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>ETHINYL ESTRADIOL\NORGESTIMATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PAXIL</medicinalproduct>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>20 MILLIGRAM, QD</drugdosagetext>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>PAROXETINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ALBUTEROL</medicinalproduct>
        <drugdosagetext>UNK, PRN</drugdosagetext>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>ALBUTEROL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>DIPHENHYDRAMINE</medicinalproduct>
        <drugdosagetext>UNK, PRN</drugdosagetext>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>DIPHENHYDRAMINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>VITAMINS</medicinalproduct>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>VITAMINS</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>EPIPEN</medicinalproduct>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>EPINEPHRINE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211201</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20386214</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220127</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220127</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-ALLERGAN-2132262US</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Off label use</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Product preparation issue</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug ineffective</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug ineffective for unapproved indication</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BOTOX COSMETIC</medicinalproduct>
        <drugbatchnumb>C6569</drugbatchnumb>
        <drugauthorizationnumb>1145103000</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>UNK UNK, SINGLE</drugdosagetext>
        <drugdosageform>Powder for injection</drugdosageform>
        <drugindication>Skin wrinkling</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ONABOTULINUMTOXINA</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BOTOX COSMETIC</medicinalproduct>
        <drugbatchnumb>C6569</drugbatchnumb>
        <drugauthorizationnumb>1145103000</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>UNK UNK, SINGLE</drugdosagetext>
        <drugdosageform>Powder for injection</drugdosageform>
        <drugindication>Skin wrinkling</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ONABOTULINUMTOXINA</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BOTOX COSMETIC</medicinalproduct>
        <drugbatchnumb>C6569</drugbatchnumb>
        <drugauthorizationnumb>1145103000</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>UNK UNK, SINGLE</drugdosagetext>
        <drugdosageform>Powder for injection</drugdosageform>
        <drugindication>Skin wrinkling</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ONABOTULINUMTOXINA</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BOTOX COSMETIC</medicinalproduct>
        <drugbatchnumb>C6569</drugbatchnumb>
        <drugauthorizationnumb>1145103000</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>UNK UNK, SINGLE</drugdosagetext>
        <drugdosageform>Powder for injection</drugdosageform>
        <drugindication>Skin wrinkling</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ONABOTULINUMTOXINA</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20316183</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220110</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220110</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-PBT-004210</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
      <literaturereference>Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P et. al. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2021 Dec;27(12):1003.e1-1003.e13.</literaturereference>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>31</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientagegroup>5</patientagegroup>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Product use in unapproved indication</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug ineffective</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Chronic graft versus host disease</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TACROLIMUS</medicinalproduct>
        <drugauthorizationnumb>090802</drugauthorizationnumb>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Prophylaxis against graft versus host disease</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>TACROLIMUS</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MYCOPHENOLATE MOFETIL</medicinalproduct>
        <drugauthorizationnumb>82916.00.00</drugauthorizationnumb>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Prophylaxis against graft versus host disease</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MYCOPHENOLATE MOFETIL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CYCLOPHOSPHAMIDE</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Prophylaxis against graft versus host disease</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>CYCLOPHOSPHAMIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20312352</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220108</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220108</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0279781</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Anxiety</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCODONE HYDROCHLORIDE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HYDROCODONE BITARTRATE AND ACETAMINOPHEN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ACETAMINOPHEN\HYDROCODONE BITARTRATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCODONE HYDROCHLORIDE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MORPHINE SULFATE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Oral solution</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MORPHINE SULFATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCODONE HYDROCHLORIDE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Oral solution</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HYDROMORPHONE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>HYDROMORPHONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MORPHINE SULFATE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MORPHINE SULFATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCODONE HYDROCHLORIDE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TRAMADOL</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>TRAMADOL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>METHADOSE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>METHADONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ROXICODONE</medicinalproduct>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LORCET</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ACETAMINOPHEN\HYDROCODONE BITARTRATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PERCODAN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ASPIRIN\OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BUPRENORPHINE HYDROCHLORIDE\NALOXONE HYDROCHLORIDE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Sublingual tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>BUPRENORPHINE HYDROCHLORIDE\NALOXONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ACETAMINOPHEN\CODEINE PHOSPHATE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ACETAMINOPHEN\CODEINE PHOSPHATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>FENTANYL</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Transdermal patch</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>FENTANYL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OPANA</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYMORPHONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>METHADONE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>METHADONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MEPERIDINE HYDROCHLORIDE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MEPERIDINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20290019</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220104</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220104</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-GLAXOSMITHKLINE-US2022GSK000888</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Prostate cancer</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ZANTAC</medicinalproduct>
        <drugbatchnumb>UNK</drugbatchnumb>
        <drugauthorizationnumb>018703</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN AT THIS TIME PRESCRIPTION</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>198301</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201912</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ZANTAC</medicinalproduct>
        <drugbatchnumb>UNK</drugbatchnumb>
        <drugauthorizationnumb>018703</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN AT THIS TIME PRESCRIPTION</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>198301</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201912</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20339036</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220117</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220117</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-BoehringerIngelheim-2022-BI-107720</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>US_MI</duplicatesource>
      <duplicatenumb>BI-US-14012022-1316-0029573</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>88</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientagegroup>6</patientagegroup>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Cardiac arrest</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OFEV</medicinalproduct>
        <drugbatchnumb>unknown</drugbatchnumb>
        <drugauthorizationnumb>205832</drugauthorizationnumb>
        <drugstructuredosagenumb>150</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosageform>Capsule</drugdosageform>
        <drugindication>Idiopathic pulmonary fibrosis</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202112</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20220107</drugenddate>
        <drugtreatmentduration>37</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <activesubstance>
          <activesubstancename>NINTEDANIB</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20220107</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20293815</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220104</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220104</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0254480</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>VICODIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ACETAMINOPHEN\HYDROCODONE BITARTRATE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20384120</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedate>20220127</receivedate>
    <receiptdate>20220127</receiptdate>
    <fulfillexpeditecriteria>3</fulfillexpeditecriteria>
    <authoritynumb>601096</authoritynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>2</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>33</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>116.1</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Erythema</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Erythema</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Ocular hyperaemia</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Chest discomfort</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Throat tightness</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Swollen tongue</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Lip swelling</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Musculoskeletal discomfort</reactionmeddrapt>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BAMLANIVIMAB\ETESEVIMAB</medicinalproduct>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>COVID-19</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211222</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211222</drugenddate>
        <activesubstance>
          <activesubstancename>BAMLANIVIMAB\ETESEVIMAB</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211222</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20388251</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220128</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220128</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-ALLERGAN-2139458US</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Dizziness</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Feeling drunk</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Condition aggravated</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Off label use</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BOTOX</medicinalproduct>
        <drugauthorizationnumb>103000</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>700 UNITS, SINGLE</drugdosagetext>
        <drugdosageform>Powder for injection</drugdosageform>
        <drugindication>Muscle spasticity</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2016</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2016</drugenddate>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ONABOTULINUMTOXINA</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BOTOX</medicinalproduct>
        <drugauthorizationnumb>103000</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>600 UNITS, SINGLE</drugdosagetext>
        <drugdosageform>Powder for injection</drugdosageform>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2016</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2016</drugenddate>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ONABOTULINUMTOXINA</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BOTOX</medicinalproduct>
        <drugauthorizationnumb>103000</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>500 UNITS, SINGLE</drugdosagetext>
        <drugdosageform>Powder for injection</drugdosageform>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2016</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2016</drugenddate>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ONABOTULINUMTOXINA</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BOTOX</medicinalproduct>
        <drugauthorizationnumb>103000</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>UNK, SINGLE</drugdosagetext>
        <drugdosageform>Powder for injection</drugdosageform>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2016</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2016</drugenddate>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ONABOTULINUMTOXINA</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20160101</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20299273</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220105</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220105</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-BAYER-2022A001157</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>ENGAGE</duplicatesource>
      <duplicatenumb>US-ENGAGE-5175053</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Extra dose administered</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CLARITIN</medicinalproduct>
        <drugbatchnumb>UNK</drugbatchnumb>
        <drugauthorizationnumb>019658</drugauthorizationnumb>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 DF, BID</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>LORATADINE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20372037</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220124</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220124</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-FERRINGPH-2020FE09352</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Hypersensitivity</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Incorrect dose administered</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CLENPIQ</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>209589</drugauthorizationnumb>
        <drugdosagetext>1 BOTTLE</drugdosagetext>
        <drugdosageform>Oral solution</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20201229</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20201229</drugenddate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20201229</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20335038</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220114</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220114</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-GLAXOSMITHKLINE-US2022GSK004820</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Renal cancer</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugauthorizationnumb>018703</drugauthorizationnumb>
        <drugstructuredosagenumb>150</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>150 MG, QD</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Gastrooesophageal reflux disease</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201501</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>202003</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugauthorizationnumb>018703</drugauthorizationnumb>
        <drugdosageform>Tablet</drugdosageform>
        <drugindication>Dyspepsia</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugauthorizationnumb>018703</drugauthorizationnumb>
        <drugstructuredosagenumb>150</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>150 MG, QD</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Gastrooesophageal reflux disease</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201501</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>202003</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugauthorizationnumb>018703</drugauthorizationnumb>
        <drugdosageform>Capsule</drugdosageform>
        <drugindication>Dyspepsia</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ZANTAC</medicinalproduct>
        <drugstructuredosagenumb>150</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>150 MG, QD</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Gastrooesophageal reflux disease</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>200901</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201412</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ZANTAC</medicinalproduct>
        <drugindication>Dyspepsia</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugstructuredosagenumb>150</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>150 MG, QD</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Gastrooesophageal reflux disease</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>200901</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201412</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugindication>Dyspepsia</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20368465</safetyreportid>
    <primarysourcecountry>EG</primarysourcecountry>
    <occurcountry>EG</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220124</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220124</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>EG-NOVARTISPH-NVSC2022EG012350</companynumb>
    <primarysource>
      <reportercountry>EG</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>51</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Hepatic enzyme increased</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Vaginal haemorrhage</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Cervix carcinoma stage I</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Amnesia</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Disturbance in attention</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>GILENYA</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>22527</drugauthorizationnumb>
        <drugstructuredosagenumb>0.5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>0.5 MG, QD</drugdosagetext>
        <drugdosageform>Capsule, hard</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Multiple sclerosis</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202012</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>202110</drugenddate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>FINGOLIMOD HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20201201</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>19922056</safetyreportid>
    <primarysourcecountry>DE</primarysourcecountry>
    <occurcountry>DE</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>1</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211005</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220121</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>DE-SANOFI-00692968</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>SANOFI</duplicatesource>
      <duplicatenumb>DE-SANOFI-00695858</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>PORTAL ID</duplicatesource>
      <duplicatenumb>SanofiPVPortal20210929000652</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>SANOFI</duplicatesource>
      <duplicatenumb>DE-SANOFI-00692968</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>DE</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>45</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientagegroup>5</patientagegroup>
      <patientweight>95</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Crohn^s disease</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Diarrhoea</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Haematochezia</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Colitis ulcerative</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Gastritis erosive</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Colitis</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Terminal ileitis</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Ileal stenosis</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Gastrointestinal mucosa hyperaemia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Duodenitis</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Mucosal dryness</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Faecal calprotectin increased</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Renal failure</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Abscess intestinal</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Blood creatinine increased</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Escherichia urinary tract infection</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Dysuria</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Acute kidney injury</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Renal atrophy</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Kidney fibrosis</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Abdominal pain upper</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Weight decreased</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Hypertension</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Adverse drug reaction</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>AUBAGIO</medicinalproduct>
        <drugauthorizationnumb>202992</drugauthorizationnumb>
        <drugstructuredosagenumb>14</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugcumulativedosagenumb>35126</drugcumulativedosagenumb>
        <drugcumulativedosageunit>003</drugcumulativedosageunit>
        <drugdosagetext>14 MG, QD</drugdosagetext>
        <drugdosageform>Film-coated tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Multiple sclerosis</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140901</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211214</drugenddate>
        <drugtreatmentduration>2662</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>TERIFLUNOMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>HYDROCHLOROTHIAZIDE\RAMIPRIL</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Blood pressure management</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202111</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>HYDROCHLOROTHIAZIDE\RAMIPRIL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>HYDROCHLOROTHIAZIDE\RAMIPRIL</medicinalproduct>
        <drugindication>Hypertension</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>HYDROCHLOROTHIAZIDE\RAMIPRIL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>AMLODIPINE BESYLATE</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 DF, QD</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Hypertension</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210930</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>AMLODIPINE BESYLATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>BUDESONIDE</medicinalproduct>
        <drugstructuredosagenumb>3</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>3 DF, QD (RESISTANT TO GASTRIC JUICES) (PLEASE REDUCE TO 6 MG AFTER FOUR WEEKS)</drugdosagetext>
        <drugdosageform>Capsule, hard</drugdosageform>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>BUDESONIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CIPROFLOXACIN HYDROCHLORIDE</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosagetext>1 DF, BID DAILY</drugdosagetext>
        <drugdosageform>Film-coated tablet</drugdosageform>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20210720</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>CIPROFLOXACIN HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PANTOPRAZOLE SODIUM</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 DF, QD (RESISTANT TO GASTRIC JUICES)</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PANTOPRAZOLE SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PREDNISOLONE</medicinalproduct>
        <drugstructuredosagenumb>3.5</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>3.5 DF, QD (WITH TAPERING PLAN)</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20210725</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PREDNISOLONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>RAMIPRIL</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosagetext>1 DF, BID DAILY</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugindication>Hypertension</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RAMIPRIL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>RAMIPRIL</medicinalproduct>
        <drugdosagetext>2 ? 1</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RAMIPRIL</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20210101</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20336691</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220114</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220114</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-GLAXOSMITHKLINE-US2022GSK007201</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Breast cancer</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ZANTAC</medicinalproduct>
        <drugbatchnumb>UNK</drugbatchnumb>
        <drugauthorizationnumb>018703</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>UNK, QD</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Dyspepsia</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>199501</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201912</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ZANTAC</medicinalproduct>
        <drugauthorizationnumb>018703</drugauthorizationnumb>
        <drugdosageform>Tablet</drugdosageform>
        <drugindication>Dyspepsia</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ZANTAC</medicinalproduct>
        <drugauthorizationnumb>018703</drugauthorizationnumb>
        <drugdosageform>Tablet</drugdosageform>
        <drugindication>Abdominal discomfort</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ZANTAC</medicinalproduct>
        <drugbatchnumb>UNK</drugbatchnumb>
        <drugauthorizationnumb>018703</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>UNK, QD</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Dyspepsia</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>199501</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201912</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ZANTAC</medicinalproduct>
        <drugauthorizationnumb>018703</drugauthorizationnumb>
        <drugdosageform>Capsule</drugdosageform>
        <drugindication>Dyspepsia</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ZANTAC</medicinalproduct>
        <drugauthorizationnumb>018703</drugauthorizationnumb>
        <drugdosageform>Capsule</drugdosageform>
        <drugindication>Abdominal discomfort</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugbatchnumb>UNK</drugbatchnumb>
        <drugauthorizationnumb>018703</drugauthorizationnumb>
        <drugstructuredosagenumb>300</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>300 MG, QD</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Dyspepsia</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>199501</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201912</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugauthorizationnumb>018703</drugauthorizationnumb>
        <drugdosageform>Tablet</drugdosageform>
        <drugindication>Dyspepsia</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugauthorizationnumb>018703</drugauthorizationnumb>
        <drugdosageform>Tablet</drugdosageform>
        <drugindication>Abdominal discomfort</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugbatchnumb>UNK</drugbatchnumb>
        <drugauthorizationnumb>018703</drugauthorizationnumb>
        <drugstructuredosagenumb>300</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>300 MG, QD</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Dyspepsia</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>199501</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201912</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugauthorizationnumb>018703</drugauthorizationnumb>
        <drugdosageform>Capsule</drugdosageform>
        <drugindication>Dyspepsia</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugauthorizationnumb>018703</drugauthorizationnumb>
        <drugdosageform>Capsule</drugdosageform>
        <drugindication>Abdominal discomfort</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20386707</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220127</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220127</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-ALLERGAN-2106454US</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Lacrimation increased</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BOTOX COSMETIC</medicinalproduct>
        <drugauthorizationnumb>1145103000</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>20 UNITS, SINGLE</drugdosagetext>
        <drugdosageform>Powder for injection</drugdosageform>
        <drugindication>Skin wrinkling</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210128</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20210128</drugenddate>
        <drugtreatmentduration>1</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ONABOTULINUMTOXINA</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20210101</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20360983</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220121</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220121</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-GILEAD-2022-0565710</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientagegroup>5</patientagegroup>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pruritus</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Fatigue</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SOFOSBUVIR\VELPATASVIR</medicinalproduct>
        <drugbatchnumb>20ASV007UA</drugbatchnumb>
        <drugauthorizationnumb>214187</drugauthorizationnumb>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 DOSAGE FORM, QD</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Chronic hepatitis C</drugindication>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>SOFOSBUVIR\VELPATASVIR</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>METHADONE HYDROCHLORIDE</medicinalproduct>
        <activesubstance>
          <activesubstancename>METHADONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>20187099</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211215</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220106</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-JAZZ-2021-US-021920</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Gastrointestinal disorder</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>XYREM</medicinalproduct>
        <drugauthorizationnumb>021196</drugauthorizationnumb>
        <drugstructuredosagenumb>2.25</drugstructuredosagenumb>
        <drugstructuredosageunit>002</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosagetext>2.25 GRAM, BID</drugdosagetext>
        <drugdosageform>Oral solution</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Narcolepsy</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202011</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>202011</drugenddate>
        <actiondrug>1</actiondrug>
        <drugadditional>2</drugadditional>
        <activesubstance>
          <activesubstancename>SODIUM OXYBATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>XYREM</medicinalproduct>
        <drugauthorizationnumb>021196</drugauthorizationnumb>
        <drugdosagetext>DOSE ADJUSTMENTS</drugdosagetext>
        <drugdosageform>Oral solution</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202011</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>202011</drugenddate>
        <actiondrug>1</actiondrug>
        <drugadditional>2</drugadditional>
        <activesubstance>
          <activesubstancename>SODIUM OXYBATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>XYREM</medicinalproduct>
        <drugauthorizationnumb>021196</drugauthorizationnumb>
        <drugstructuredosagenumb>4.5</drugstructuredosagenumb>
        <drugstructuredosageunit>002</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosagetext>4.5 GRAM, BID</drugdosagetext>
        <drugdosageform>Oral solution</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202011</drugstartdate>
        <actiondrug>1</actiondrug>
        <drugadditional>2</drugadditional>
        <activesubstance>
          <activesubstancename>SODIUM OXYBATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LAMOTRIGINE</medicinalproduct>
        <drugdosagetext>25 MG TABLET</drugdosagetext>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20201104</drugstartdate>
        <activesubstance>
          <activesubstancename>LAMOTRIGINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>BUSPIRONE HCL</medicinalproduct>
        <drugdosagetext>10 MG TABLET</drugdosagetext>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20201103</drugstartdate>
        <activesubstance>
          <activesubstancename>BUSPIRONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>L-LYSINE [LYSINE]</medicinalproduct>
        <drugdosagetext>MG TABLET</drugdosagetext>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210711</drugstartdate>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20293631</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>1</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220104</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220104</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0249265</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MORPHINE SULFATE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MORPHINE SULFATE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20378373</safetyreportid>
    <primarysourcecountry>CN</primarysourcecountry>
    <occurcountry>CN</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220126</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220126</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>CN-SA-SAC20220117001114</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>REGENERON PHARMACEUTICALS, INC.</duplicatesource>
      <duplicatenumb>CN-REGENERON PHARMACEUTICALS, INC.-2022-016896</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>SA</duplicatesource>
      <duplicatenumb>CN-SA-SAC20220117001114</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>SA</duplicatesource>
      <duplicatenumb>CN-SA-2022SA015034</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>CN</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Angina unstable</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Disease risk factor</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Cardiovascular disorder</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PRALUENT</medicinalproduct>
        <drugauthorizationnumb>125559</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211021</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211221</drugenddate>
        <drugtreatmentduration>62</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <activesubstance>
          <activesubstancename>ALIROCUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>REPATHA</medicinalproduct>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>EVOLOCUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>EZETIMIBE</medicinalproduct>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>EZETIMIBE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20210101</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20305408</safetyreportid>
    <primarysourcecountry>CN</primarysourcecountry>
    <occurcountry>CN</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220106</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220106</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>CN-Merck Healthcare KGaA-9289973</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>Merck Healthcare KGaA</duplicatesource>
      <duplicatenumb>CN-Merck Healthcare KGaA-9289973</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>DE</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>77</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>55</patientweight>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Palpitations</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Chills</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pyrexia</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ERBITUX</medicinalproduct>
        <drugbatchnumb>G00X7P</drugbatchnumb>
        <drugauthorizationnumb>125084</drugauthorizationnumb>
        <drugstructuredosagenumb>800</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>800 MG, UNKNOWN</drugdosagetext>
        <drugadministrationroute>041</drugadministrationroute>
        <drugindication>Rectal cancer metastatic</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211216</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211216</drugenddate>
        <drugtreatmentduration>1</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>CETUXIMAB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CAPECITABINE</medicinalproduct>
        <drugbatchnumb>201819KF</drugbatchnumb>
        <drugstructuredosagenumb>1.5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1.5 MG, UNK</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Rectal cancer metastatic</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211216</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211216</drugenddate>
        <drugtreatmentduration>1</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <activesubstance>
          <activesubstancename>CAPECITABINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>BICALUTAMIDE</medicinalproduct>
        <drugbatchnumb>D10410</drugbatchnumb>
        <drugstructuredosagenumb>50</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>50 MG, DAILY</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Rectal cancer metastatic</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211216</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211216</drugenddate>
        <activesubstance>
          <activesubstancename>BICALUTAMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>SODIUM CHLORIDE</medicinalproduct>
        <drugbatchnumb>210929603</drugbatchnumb>
        <drugstructuredosagenumb>250</drugstructuredosagenumb>
        <drugstructuredosageunit>012</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>250 ML, DAILY</drugdosagetext>
        <drugadministrationroute>041</drugadministrationroute>
        <drugindication>Medication dilution</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211216</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211216</drugenddate>
        <activesubstance>
          <activesubstancename>SODIUM CHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211216</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20314746</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220110</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220110</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-PFIZER INC-202200004871</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Anaphylactic shock</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Dyspnoea</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug hypersensitivity</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Urticaria</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CELECOXIB</medicinalproduct>
        <drugauthorizationnumb>20998</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>CELECOXIB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CIPROFLOXACIN</medicinalproduct>
        <drugauthorizationnumb>077245</drugauthorizationnumb>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>CIPROFLOXACIN</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20323277</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220111</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220111</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-NOVOPROD-858794</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Neck pain</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Lethargy</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RYBELSUS</medicinalproduct>
        <drugauthorizationnumb>213051</drugauthorizationnumb>
        <drugstructuredosagenumb>3</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>3 MG, QD</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>SEMAGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20350690</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedate>20220117</receivedate>
    <receiptdate>20220117</receiptdate>
    <fulfillexpeditecriteria>3</fulfillexpeditecriteria>
    <authoritynumb>599488</authoritynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>2</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>41</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>51.75</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Fibroadenoma of breast</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Heavy menstrual bleeding</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Dysmenorrhoea</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Product substitution issue</reactionmeddrapt>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>NORETHINDRONE AND ETHINYL ESTRADIOL, AND FERROUS FUMARATE</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>FREQUENCY : DAILY;?</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Contraception</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20120101</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20170101</drugenddate>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>ETHINYL ESTRADIOL\NORETHINDRONE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20170101</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20301649</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220105</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220105</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-PFIZER INC-202200008834</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>75</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Death</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>IBRANCE</medicinalproduct>
        <drugauthorizationnumb>207103</drugauthorizationnumb>
        <drugstructuredosagenumb>125</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>125 MG</drugdosagetext>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PALBOCICLIB</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20337199</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220114</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220114</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-SA-SAC20220107001025</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>SA</duplicatesource>
      <duplicatenumb>US-SA-SAC20220107001025</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>PORTAL ID</duplicatesource>
      <duplicatenumb>SanofiPVPortal20220107000146</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientagegroup>5</patientagegroup>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Arthralgia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Condition aggravated</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Joint swelling</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>KEVZARA</medicinalproduct>
        <drugauthorizationnumb>761037</drugauthorizationnumb>
        <drugstructuredosagenumb>200</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>2</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>200 MG, QOW</drugdosagetext>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Rheumatoid arthritis</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20171115</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>SARILUMAB</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20326912</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220112</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220112</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-CELGENE-USA-20220102554</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>cvscaremark</duplicatesource>
      <duplicatenumb>728020</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Diarrhoea</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Abdominal discomfort</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <drugbatchnumb>A3462A</drugbatchnumb>
        <drugauthorizationnumb>021880</drugauthorizationnumb>
        <drugstructuredosagenumb>25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>25 MILLIGRAM</drugdosagetext>
        <drugdosageform>Capsules</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Plasma cell myeloma</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201712</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <drugbatchnumb>A3462A</drugbatchnumb>
        <drugauthorizationnumb>021880</drugauthorizationnumb>
        <drugstructuredosagenumb>15</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>15 MILLIGRAM</drugdosagetext>
        <drugdosageform>Capsules</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201803</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <drugbatchnumb>A3462A</drugbatchnumb>
        <drugauthorizationnumb>021880</drugauthorizationnumb>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>10 MILLIGRAM</drugdosagetext>
        <drugdosageform>Capsules</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201806</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <drugbatchnumb>A3462A</drugbatchnumb>
        <drugauthorizationnumb>021880</drugauthorizationnumb>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>21</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>28</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>5 MILLIGRAM</drugdosagetext>
        <drugdosageform>Capsules</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201910</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>4</safetyreportversion>
    <safetyreportid>20048508</safetyreportid>
    <primarysourcecountry>FR</primarysourcecountry>
    <occurcountry>FR</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211109</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220112</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>FR-TAKEDA-2021TUS069272</companynumb>
    <primarysource>
      <reportercountry>FR</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>72</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>61.678</patientweight>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Device related infection</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TEDUGLUTIDE</medicinalproduct>
        <drugauthorizationnumb>203441</drugauthorizationnumb>
        <drugstructuredosagenumb>3.2</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugcumulativedosagenumb>1545.6</drugcumulativedosagenumb>
        <drugcumulativedosageunit>003</drugcumulativedosageunit>
        <drugdosagetext>3.2 MILLIGRAM, QD</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Short-bowel syndrome</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20200624</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211019</drugenddate>
        <drugtreatmentduration>483</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>TEDUGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TEDUGLUTIDE</medicinalproduct>
        <drugauthorizationnumb>203441</drugauthorizationnumb>
        <drugstructuredosagenumb>3.2</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugcumulativedosagenumb>1545.6</drugcumulativedosagenumb>
        <drugcumulativedosageunit>003</drugcumulativedosageunit>
        <drugdosagetext>3.2 MILLIGRAM, QD</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Short-bowel syndrome</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20200624</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211019</drugenddate>
        <drugtreatmentduration>483</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>TEDUGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TEDUGLUTIDE</medicinalproduct>
        <drugauthorizationnumb>203441</drugauthorizationnumb>
        <drugstructuredosagenumb>3.2</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugcumulativedosagenumb>1545.6</drugcumulativedosagenumb>
        <drugcumulativedosageunit>003</drugcumulativedosageunit>
        <drugdosagetext>3.2 MILLIGRAM, QD</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Short-bowel syndrome</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20200624</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211019</drugenddate>
        <drugtreatmentduration>483</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>TEDUGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TEDUGLUTIDE</medicinalproduct>
        <drugauthorizationnumb>203441</drugauthorizationnumb>
        <drugstructuredosagenumb>3.2</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugcumulativedosagenumb>1545.6</drugcumulativedosagenumb>
        <drugcumulativedosageunit>003</drugcumulativedosageunit>
        <drugdosagetext>3.2 MILLIGRAM, QD</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Short-bowel syndrome</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20200624</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211019</drugenddate>
        <drugtreatmentduration>483</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>TEDUGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>IMODIUM</medicinalproduct>
        <drugstructuredosagenumb>6</drugstructuredosagenumb>
        <drugstructuredosageunit>002</drugstructuredosageunit>
        <drugdosagetext>6 GRAM</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <activesubstance>
          <activesubstancename>LOPERAMIDE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>NOPRAL</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>OLIMEL</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <activesubstance>
          <activesubstancename>AMINO ACIDS\DEXTROSE\SOYBEAN OIL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>VANCOMYCIN</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <activesubstance>
          <activesubstancename>VANCOMYCIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CLOXACILLIN SODIUM</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugseparatedosagenumb>4</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 INTERNATIONAL UNIT, QID</drugdosagetext>
        <drugadministrationroute>030</drugadministrationroute>
        <drugindication>Vascular device infection</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211030</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211109</drugenddate>
        <drugtreatmentduration>11</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <activesubstance>
          <activesubstancename>CLOXACILLIN SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS\MAGNESIUM GLYCEROPHOSPHATE\PHOSP</medicinalproduct>
        <drugstructuredosagenumb>50</drugstructuredosagenumb>
        <drugstructuredosageunit>031</drugstructuredosageunit>
        <drugseparatedosagenumb>3</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>50 GTT DROPS, TID</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Hypophosphataemia</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211117</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211124</drugenddate>
        <drugtreatmentduration>8</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <activesubstance>
          <activesubstancename>CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS\MAGNESIUM GLYCEROPHOSPHATE\PHOSPHORIC ACID\SODIUM PHOSPHATE, D</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS\MAGNESIUM GLYCEROPHOSPHATE\PHOSP</medicinalproduct>
        <drugindication>Blood sodium decreased</drugindication>
        <activesubstance>
          <activesubstancename>CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS\MAGNESIUM GLYCEROPHOSPHATE\PHOSPHORIC ACID\SODIUM PHOSPHATE, D</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PERINDOPRIL ARGININE</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 DOSAGE FORM, QD</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Hypertension</drugindication>
        <activesubstance>
          <activesubstancename>PERINDOPRIL ARGININE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211019</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>8</safetyreportversion>
    <safetyreportid>19772028</safetyreportid>
    <primarysourcecountry>CA</primarysourcecountry>
    <occurcountry>CA</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20210831</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220124</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>CA-TAKEDA-2018MPI014438</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>Adverse reaction report number</duplicatesource>
      <duplicatenumb>E2B_04619091</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>Adverse reaction report number</duplicatesource>
      <duplicatenumb>E2B_04619019</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>CA</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>67</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Cardiac failure</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Clostridium difficile colitis</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Neuropathy peripheral</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Haemorrhoids</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Fall</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Dyspnoea</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Chest discomfort</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>COVID-19 immunisation</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Abdominal pain upper</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>COVID-19</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Constipation</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Product use issue</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Off label use</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>IXAZOMIB</medicinalproduct>
        <drugbatchnumb>1761989</drugbatchnumb>
        <drugauthorizationnumb>208462</drugauthorizationnumb>
        <drugstructuredosagenumb>3</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>3 MILLIGRAM</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Plasma cell myeloma</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20170717</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20170819</drugenddate>
        <drugtreatmentduration>34</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>IXAZOMIB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>IXAZOMIB</medicinalproduct>
        <drugauthorizationnumb>208462</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20170922</drugstartdate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>IXAZOMIB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>IXAZOMIB</medicinalproduct>
        <drugauthorizationnumb>208462</drugauthorizationnumb>
        <drugstructuredosagenumb>2.3</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>2.3 MILLIGRAM</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20180727</drugstartdate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>IXAZOMIB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>IXAZOMIB</medicinalproduct>
        <drugauthorizationnumb>208462</drugauthorizationnumb>
        <drugstructuredosagenumb>2.3</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>2.3 MILLIGRAM</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201809</drugstartdate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>IXAZOMIB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>IXAZOMIB</medicinalproduct>
        <drugbatchnumb>1779673,17897419</drugbatchnumb>
        <drugauthorizationnumb>208462</drugauthorizationnumb>
        <drugstructuredosagenumb>3</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>3 MILLIGRAM</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210820</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20220107</drugenddate>
        <drugtreatmentduration>141</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>IXAZOMIB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DEXAMETHASONE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>UNK</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>DEXAMETHASONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PIOGLITAZONE</medicinalproduct>
        <drugstructuredosagenumb>15</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>15 MILLIGRAM, QD</drugdosagetext>
        <drugdosageform>UNK</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Diabetes mellitus</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210517</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PIOGLITAZONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ONDANSETRON</medicinalproduct>
        <drugstructuredosagenumb>8</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>8 MILLIGRAM</drugdosagetext>
        <drugdosageform>UNK</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Premedication</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20180724</drugstartdate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>ONDANSETRON</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>COVID-19 VACCINE NOS</medicinalproduct>
        <drugstructuredosagenumb>30</drugstructuredosagenumb>
        <drugstructuredosageunit>004</drugstructuredosageunit>
        <drugdosagetext>30 MICROGRAM</drugdosagetext>
        <drugadministrationroute>030</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210825</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>COVID-19 VACCINE NOS</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>COVID-19 VACCINE NOS</medicinalproduct>
        <drugstructuredosagenumb>30</drugstructuredosagenumb>
        <drugstructuredosageunit>004</drugstructuredosageunit>
        <drugdosagetext>30 MICROGRAM</drugdosagetext>
        <drugadministrationroute>030</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210922</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>COVID-19 VACCINE NOS</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>GLICLAZIDE</medicinalproduct>
        <drugstructuredosagenumb>30</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>30 MILLIGRAM, QD</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Blood glucose increased</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210224</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20210510</drugenddate>
        <drugtreatmentduration>76</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>GLICLAZIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>GLICLAZIDE</medicinalproduct>
        <drugstructuredosagenumb>15</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>15 MILLIGRAM, QD</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210520</drugstartdate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>GLICLAZIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CYCLOPHOSPHAMIDE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20170819</drugenddate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>CYCLOPHOSPHAMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CYCLOPHOSPHAMIDE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20170922</drugstartdate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>CYCLOPHOSPHAMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CYCLOPHOSPHAMIDE</medicinalproduct>
        <drugstructuredosagenumb>50</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>2</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>50 MILLIGRAM, QOD</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20201120</drugstartdate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>CYCLOPHOSPHAMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>5 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20180406</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20180529</drugenddate>
        <drugtreatmentduration>54</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>5 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20180615</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20180628</drugenddate>
        <drugtreatmentduration>14</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20180724</drugenddate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ASPIRIN                            /00002701/</medicinalproduct>
        <drugstructuredosagenumb>81</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>81 MILLIGRAM, QD</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20180427</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>EPREX</medicinalproduct>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>UNK, 1/WEEK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20180529</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ERYTHROPOIETIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>QUININE</medicinalproduct>
        <drugstructuredosagenumb>200</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>2</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>200 MILLIGRAM, QOD</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Muscle spasms</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20180529</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>QUININE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ROSUVASTATIN</medicinalproduct>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>5 MILLIGRAM, QD</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <actiondrug>2</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>ROSUVASTATIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ACYCLOVIR                          /00587301/</medicinalproduct>
        <drugstructuredosagenumb>200</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>200 MILLIGRAM, BID</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PREDNISONE</medicinalproduct>
        <drugstructuredosagenumb>50</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>2</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>50 MILLIGRAM, QOD</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20201119</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>PREDNISONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PREDNISONE</medicinalproduct>
        <drugstructuredosagenumb>25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>2</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>25 MILLIGRAM, QOD</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210202</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>PREDNISONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PANTOPRAZOLE</medicinalproduct>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>40 MILLIGRAM, QD</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <activesubstance>
          <activesubstancename>PANTOPRAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>AMLODIPINE</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>10 MILLIGRAM, QD</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <activesubstance>
          <activesubstancename>AMLODIPINE BESYLATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ATENOLOL</medicinalproduct>
        <drugstructuredosagenumb>25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>25 MILLIGRAM, QD</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <activesubstance>
          <activesubstancename>ATENOLOL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TERAZOSIN</medicinalproduct>
        <drugstructuredosagenumb>2</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>2 MILLIGRAM, QD</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <activesubstance>
          <activesubstancename>TERAZOSIN HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>NITROGLYCERIN</medicinalproduct>
        <drugstructuredosagenumb>0.4</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosagetext>0.4 MILLIGRAM, Q1HR</drugdosagetext>
        <drugadministrationroute>062</drugadministrationroute>
        <activesubstance>
          <activesubstancename>NITROGLYCERIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FERROUS FUMARATE</medicinalproduct>
        <drugstructuredosagenumb>300</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>300 MILLIGRAM, QD</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <activesubstance>
          <activesubstancename>FERROUS FUMARATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CALCIUM\CHOLECALCIFEROL\MAGNESIUM</medicinalproduct>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>UNK UNK, QD</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <activesubstance>
          <activesubstancename>CALCIUM\CHOLECALCIFEROL\MAGNESIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>BACLOFEN</medicinalproduct>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>5 MILLIGRAM, BID</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <activesubstance>
          <activesubstancename>BACLOFEN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LINAGLIPTIN</medicinalproduct>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>5 MILLIGRAM, QD</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <activesubstance>
          <activesubstancename>LINAGLIPTIN</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211024</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20336599</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220114</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220114</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PFIZER INC-2021800727</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>60</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Arthralgia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Swelling</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Ear infection</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Depressed mood</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>XELJANZ XR</medicinalproduct>
        <drugauthorizationnumb>208246</drugauthorizationnumb>
        <drugstructuredosagenumb>11</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>11 MG, 1X/DAY</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Rheumatoid arthritis</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2020</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>202112</drugenddate>
        <actiondrug>1</actiondrug>
        <drugadditional>2</drugadditional>
        <activesubstance>
          <activesubstancename>TOFACITINIB CITRATE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20377104</safetyreportid>
    <primarysourcecountry>BR</primarysourcecountry>
    <occurcountry>BR</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220125</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220125</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>BR-TAKEDA-2022TJP008967</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>TAKEDA</duplicatesource>
      <duplicatenumb>BR-TAKEDA-2022TJP008195</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>BR</reportercountry>
      <qualification>1</qualification>
      <literaturereference>de Oliveira LMM, Jardim LL, Santana MAP, Cerqueira MH, Lorenzato CS, Franco VKB, et al. Effect of the first factor VIII infusions on immunological biomarkers in previously untreated patients with hemophilia a from the HEMFIL study. Thrombosis and Haemostasis. 2021;121(7):891-9</literaturereference>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientagegroup>3</patientagegroup>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Anti factor VIII antibody positive</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RECOMBINATE</medicinalproduct>
        <drugauthorizationnumb>103375</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Powder and solvent for solution for injection</drugdosageform>
        <drugadministrationroute>050</drugadministrationroute>
        <drugindication>Factor VIII deficiency</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20372760</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220125</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220125</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-ELI_LILLY_AND_COMPANY-US202201008898</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Fatigue</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Visual impairment</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Incorrect dose administered</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BASAGLAR</medicinalproduct>
        <drugauthorizationnumb>205692</drugauthorizationnumb>
        <drugdosagetext>UNK UNK, UNKNOWN</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>INSULIN GLARGINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BASAGLAR</medicinalproduct>
        <drugauthorizationnumb>205692</drugauthorizationnumb>
        <drugdosagetext>UNK UNK, UNKNOWN</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>INSULIN GLARGINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BASAGLAR</medicinalproduct>
        <drugauthorizationnumb>205692</drugauthorizationnumb>
        <drugdosagetext>UNK UNK, UNKNOWN</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>INSULIN GLARGINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BASAGLAR</medicinalproduct>
        <drugauthorizationnumb>205692</drugauthorizationnumb>
        <drugdosagetext>UNK UNK, UNKNOWN</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>INSULIN GLARGINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BASAGLAR</medicinalproduct>
        <drugauthorizationnumb>205692</drugauthorizationnumb>
        <drugdosagetext>UNK UNK, UNKNOWN</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>INSULIN GLARGINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BASAGLAR</medicinalproduct>
        <drugbatchnumb>D435768C</drugbatchnumb>
        <drugauthorizationnumb>205692</drugauthorizationnumb>
        <drugdosagetext>UNK UNK, UNKNOWN</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>INSULIN GLARGINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BASAGLAR</medicinalproduct>
        <drugbatchnumb>D435768C</drugbatchnumb>
        <drugauthorizationnumb>205692</drugauthorizationnumb>
        <drugdosagetext>UNK UNK, UNKNOWN</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>INSULIN GLARGINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BASAGLAR</medicinalproduct>
        <drugbatchnumb>D405291E</drugbatchnumb>
        <drugauthorizationnumb>205692</drugauthorizationnumb>
        <drugstructuredosagenumb>30</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>30 U, BID</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>INSULIN GLARGINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BASAGLAR</medicinalproduct>
        <drugbatchnumb>D405291E</drugbatchnumb>
        <drugauthorizationnumb>205692</drugauthorizationnumb>
        <drugstructuredosagenumb>30</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>30 U, BID</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>INSULIN GLARGINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BASAGLAR</medicinalproduct>
        <drugbatchnumb>D040265A</drugbatchnumb>
        <drugauthorizationnumb>205692</drugauthorizationnumb>
        <drugdosagetext>UNK UNK, UNKNOWN</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>INSULIN GLARGINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BASAGLAR</medicinalproduct>
        <drugbatchnumb>D040265A</drugbatchnumb>
        <drugauthorizationnumb>205692</drugauthorizationnumb>
        <drugdosagetext>UNK UNK, UNKNOWN</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>INSULIN GLARGINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BASAGLAR</medicinalproduct>
        <drugbatchnumb>D018683C</drugbatchnumb>
        <drugauthorizationnumb>205692</drugauthorizationnumb>
        <drugdosagetext>UNK UNK, UNKNOWN</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>INSULIN GLARGINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BASAGLAR</medicinalproduct>
        <drugbatchnumb>D018683C</drugbatchnumb>
        <drugauthorizationnumb>205692</drugauthorizationnumb>
        <drugdosagetext>UNK UNK, UNKNOWN</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>INSULIN GLARGINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>NOVOLOG</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>INSULIN ASPART</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20318773</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220110</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220110</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-INCYTE CORPORATION-2022IN000112</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Product availability issue</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>JAKAFI</medicinalproduct>
        <drugbatchnumb>1848574</drugbatchnumb>
        <drugauthorizationnumb>202192</drugauthorizationnumb>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>20 MILLIGRAM, QD</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20180628</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RUXOLITINIB</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20299607</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220105</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220105</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-009507513-2112USA003793</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientweight>55.329</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Urinary tract infection</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Gingival bleeding</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Heart rate increased</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Dehydration</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Weight decreased</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Insomnia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Hypertension</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Fatigue</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Asthenia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Decreased appetite</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Nausea</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Vomiting</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Constipation</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Product use in unapproved indication</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>KEYTRUDA</medicinalproduct>
        <drugauthorizationnumb>125514</drugauthorizationnumb>
        <drugstructuredosagenumb>200</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>3</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>200 MILLIGRAM, Q3W</drugdosagetext>
        <drugdosageform>Powder for injection</drugdosageform>
        <drugindication>Ovarian cancer</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PEMBROLIZUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ZEJULA</medicinalproduct>
        <drugbatchnumb>2054131</drugbatchnumb>
        <drugstructuredosagenumb>200</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>200 MILLIGRAM, QD</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Ovarian cancer</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210923</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>NIRAPARIB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ATIVAN</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <activesubstance>
          <activesubstancename>LORAZEPAM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LEVAQUIN</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <activesubstance>
          <activesubstancename>LEVOFLOXACIN</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20375295</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220125</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220125</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-MYLANLABS-2022M1006633</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>2</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>51</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Neutropenia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CLOZAPINE</medicinalproduct>
        <drugauthorizationnumb>075417</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>CLOZAPINE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20220117</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20371120</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220124</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220124</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-VIIV HEALTHCARE LIMITED-US2022AMR011014</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Wrong technique in device usage process</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CABENUVA</medicinalproduct>
        <drugauthorizationnumb>212888</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Suspension for injection</drugdosageform>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>CABOTEGRAVIR\RILPIVIRINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CABENUVA</medicinalproduct>
        <drugauthorizationnumb>212888</drugauthorizationnumb>
        <drugdosageform>Suspension for injection</drugdosageform>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>CABOTEGRAVIR\RILPIVIRINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CABENUVA</medicinalproduct>
        <drugauthorizationnumb>212888</drugauthorizationnumb>
        <drugdosageform>Suspension for injection</drugdosageform>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>CABOTEGRAVIR\RILPIVIRINE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>20196210</safetyreportid>
    <primarysourcecountry>CA</primarysourcecountry>
    <occurcountry>CA</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211216</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220114</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>CA-BAYER-2021-055675</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>BAYER</duplicatesource>
      <duplicatenumb>CA-BAYER-2021-055675</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>MMM</duplicatesource>
      <duplicatenumb>CA-MMM-PSP-NWIHEU4O</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>CA</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Hospitalisation</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Cerebrovascular accident</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Lacrimation increased</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>EYLEA</medicinalproduct>
        <drugauthorizationnumb>125387</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugindication>Diabetic retinal oedema</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210203</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>AFLIBERCEPT</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20210101</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>20040956</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211107</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220125</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-SA-SAC20211102001227</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>PORTAL ID</duplicatesource>
      <duplicatenumb>SanofiPVPortal20220119000180</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>AE Record ID</duplicatesource>
      <duplicatenumb>AE00545524</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>SA</duplicatesource>
      <duplicatenumb>US-SA-SAC20211102001227</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>PORTAL ID</duplicatesource>
      <duplicatenumb>SanofiPVPortal20211030000035</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>26</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientagegroup>5</patientagegroup>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Product dose omission issue</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DUPIXENT</medicinalproduct>
        <drugauthorizationnumb>761055</drugauthorizationnumb>
        <drugstructuredosagenumb>300</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>2</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>300 MG, QOW</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202110</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>202110</drugenddate>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>DUPILUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211027</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20271898</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220101</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220101</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0252775</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MS CONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MORPHINE SULFATE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20345293</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220118</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220118</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-CELGENE-USA-20220103482</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientweight>86.714</patientweight>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Neutrophil count decreased</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>POMALYST</medicinalproduct>
        <drugbatchnumb>C2452A</drugbatchnumb>
        <drugstructuredosagenumb>4</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>4 MILLIGRAM</drugdosagetext>
        <drugdosageform>Capsules</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Plasma cell myeloma</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202108</drugstartdate>
        <actiondrug>4</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>POMALIDOMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ELIQUIS</medicinalproduct>
        <drugdosageform>Unknown</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>APIXABAN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>KEPPRA</medicinalproduct>
        <drugdosageform>Unknown</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>LEVETIRACETAM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>XGEVA</medicinalproduct>
        <drugdosageform>Unknown</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>DENOSUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>DEXAMETHASONE</medicinalproduct>
        <drugdosageform>Unknown</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>DEXAMETHASONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>VELCADE</medicinalproduct>
        <drugdosageform>Unknown</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>BORTEZOMIB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ACYCLOVIR</medicinalproduct>
        <drugdosageform>Unknown</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>ACYCLOVIR</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TRAMADOL</medicinalproduct>
        <drugdosageform>Unknown</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>TRAMADOL</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20373200</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220125</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220125</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-ABBVIE-22K-163-4246490-00</companynumb>
    <primarysource>
      <reportercountry>COUNTRY NOT SPECIFIED</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Disease progression</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>VENCLEXTA</medicinalproduct>
        <drugbatchnumb>1151243</drugbatchnumb>
        <drugauthorizationnumb>208573</drugauthorizationnumb>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>VENETOCLAX</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20337915</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220114</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220114</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-SANOFI-00927524</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>SANOFI</duplicatesource>
      <duplicatenumb>US-SANOFI-00927524</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientagegroup>5</patientagegroup>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>COVID-19</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DUPIXENT</medicinalproduct>
        <drugauthorizationnumb>761055</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Eczema</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202104</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>DUPILUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DUPIXENT</medicinalproduct>
        <drugauthorizationnumb>761055</drugauthorizationnumb>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugindication>Asthma</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>DUPILUMAB</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>20226701</safetyreportid>
    <primarysourcecountry>IT</primarysourcecountry>
    <occurcountry>IT</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211224</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220113</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <authoritynumb>IT-MINISAL02-822522</authoritynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>MINISAL02</duplicatesource>
      <duplicatenumb>IT-MINISAL02-822522</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>MINISAL02</duplicatesource>
      <duplicatenumb>IT-MINISAL02-822522</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>MINISAL02</duplicatesource>
      <duplicatenumb>IT-MINISAL02-822522</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>IT</reportercountry>
      <qualification>2</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>8</patientonsetage>
      <patientonsetageunit>802</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Dysentery</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Irritability</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pyrexia</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MENINGOCOCCAL GROUP B VACCINE</medicinalproduct>
        <drugbatchnumb>ABXB81DA</drugbatchnumb>
        <drugauthorizationnumb>125546</drugauthorizationnumb>
        <drugdosageform>Suspension for injection in pre-filled syringe</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Prophylaxis</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211207</drugstartdate>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>MENINGOCOCCAL GROUP B VACCINE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211207</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20286969</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220103</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220103</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0276851</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Overdose</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20355695</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220120</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220120</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-008229</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>89</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Cardiac failure congestive</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ELIQUIS</medicinalproduct>
        <drugauthorizationnumb>202155</drugauthorizationnumb>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>5 MILLIGRAM, BID</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Cerebrovascular accident prophylaxis</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>APIXABAN</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20220111</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20386634</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220127</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220127</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-MMM-GKW5OQ8Z</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>36</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Skin wrinkling</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Condition aggravated</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Eyelid ptosis</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BOTOX</medicinalproduct>
        <drugauthorizationnumb>103000</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>UNK, SINGLE</drugdosagetext>
        <drugdosageform>Powder for injection</drugdosageform>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ONABOTULINUMTOXINA</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20201130</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>4</safetyreportversion>
    <safetyreportid>18485527</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20201110</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220113</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-GILEAD-2020-0503358</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>63</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientagegroup>5</patientagegroup>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Osteoporosis</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Tooth loss</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Osteopenia</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Bone density decreased</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>STRIBILD</medicinalproduct>
        <drugauthorizationnumb>203100</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>HIV infection</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2015</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2016</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>STRIBILD</medicinalproduct>
        <drugauthorizationnumb>203100</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20150124</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20151112</drugenddate>
        <drugtreatmentduration>292</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>GENVOYA</medicinalproduct>
        <drugdosageform>Tablet</drugdosageform>
        <activesubstance>
          <activesubstancename>COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR ALAFENAMIDE FUMARATE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20190801</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20310376</safetyreportid>
    <primarysourcecountry>SE</primarysourcecountry>
    <occurcountry>SE</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220107</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220107</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <authoritynumb>SE-MPA-2021-094550</authoritynumb>
    <primarysource>
      <reportercountry>SE</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>76</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Muscle twitching</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>General physical health deterioration</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>AMITRIPTYLINE</medicinalproduct>
        <drugauthorizationnumb>202446</drugauthorizationnumb>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugindication>Product used for unknown indication</drugindication>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>202110</drugenddate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>AMITRIPTYLINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BEZAFIBRATE</medicinalproduct>
        <drugstructuredosagenumb>200</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugindication>Product used for unknown indication</drugindication>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>202110</drugenddate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>BEZAFIBRATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCODONE HYDROCHLORIDE</medicinalproduct>
        <drugdosagetext>1 AS REQUIRED, DOSE: 1</drugdosagetext>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ALFACALCIDOL</medicinalproduct>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>STRENGTH:  0.25 MICROGRAM, DOSE: 1</drugdosagetext>
        <drugdosageform>Capsule, soft</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210604</drugstartdate>
        <activesubstance>
          <activesubstancename>ALFACALCIDOL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ALLOPURINOL</medicinalproduct>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>STRENGTH:  100 MG, 1X1, DOSE: 1</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <activesubstance>
          <activesubstancename>ALLOPURINOL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ATORVASTATIN</medicinalproduct>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>STRENGTH: 20 MG, DOSE: 1, 1X1</drugdosagetext>
        <drugdosageform>Film-coated tablet</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210604</drugstartdate>
        <activesubstance>
          <activesubstancename>ATORVASTATIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>BISOPROLOL</medicinalproduct>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>STRENGTH:  2.5 MG, DOSE: 1, 1X1</drugdosagetext>
        <drugdosageform>Film-coated tablet</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210604</drugstartdate>
        <activesubstance>
          <activesubstancename>BISOPROLOL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>DENTAN</medicinalproduct>
        <drugdosagetext>STRENGTH: 0.2%, 10 ML X 1-2</drugdosagetext>
        <drugdosageform>Mouthwash</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210722</drugstartdate>
        <activesubstance>
          <activesubstancename>SODIUM FLUORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FINASTERIDE</medicinalproduct>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>STRENGTH: 5 MG, DOSE: 1, 1X1</drugdosagetext>
        <drugdosageform>Film-coated tablet</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210604</drugstartdate>
        <activesubstance>
          <activesubstancename>FINASTERIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FOLIC ACID</medicinalproduct>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>STRENGTH: 1 MG, DOSE: 1, 1X1</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210604</drugstartdate>
        <activesubstance>
          <activesubstancename>FOLIC ACID</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Furix</medicinalproduct>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>STRENGTH:500 MG, DOSE: 2, 1X2</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>HUMALOG</medicinalproduct>
        <drugstructuredosagenumb>54</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>STRENGTH: 100 U / ML SOLUTION FOR INJECTION, SOLUTION IN PRE-FILLED?INJECTION</drugdosagetext>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210310</drugstartdate>
        <activesubstance>
          <activesubstancename>INSULIN LISPRO</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>HYDROCORTISONE</medicinalproduct>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>STRENGTH: 10 MG, DOSE: 2, 1X2</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210604</drugstartdate>
        <activesubstance>
          <activesubstancename>HYDROCORTISONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>HERBALS\KARAYA GUM</medicinalproduct>
        <drugdosagetext>ORAL POWDER IN SACHET, 1X1-3 OR AS REQUIRED</drugdosagetext>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210120</drugstartdate>
        <activesubstance>
          <activesubstancename>HERBALS\KARAYA GUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>INSULIN DEGLUDEC</medicinalproduct>
        <drugstructuredosagenumb>90</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>STRENGTH: 200 UNITS / ML, SOLUTION FOR INJECTION, SOLUTION IN PRE-FILLED INJECTION</drugdosagetext>
        <activesubstance>
          <activesubstancename>INSULIN DEGLUDEC</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LEVOTHYROXINE SODIUM</medicinalproduct>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>STRENGTH: 75 MICROGRAMS, 1 TABLET 4 TIMES / WEEK, DOSE: 4</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210604</drugstartdate>
        <activesubstance>
          <activesubstancename>LEVOTHYROXINE SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>MOMETASONE</medicinalproduct>
        <drugdosagetext>STRENGTH:  50 MICROGRAMS / DOSE NASAL SPRAY, SUSPENSION</drugdosagetext>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210215</drugstartdate>
        <activesubstance>
          <activesubstancename>MOMETASONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>NYSTATIN</medicinalproduct>
        <drugdosagetext>STRENGTH: 100000 IU / ML, 1 ML X 3-4</drugdosagetext>
        <drugdosageform>Oral suspension</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210908</drugstartdate>
        <activesubstance>
          <activesubstancename>NYSTATIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>POTASSIUM CHLORIDE</medicinalproduct>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>STRENGTH:  750 MG, DOSE: 1</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210722</drugstartdate>
        <activesubstance>
          <activesubstancename>POTASSIUM CHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>SEVELAMER CARBONATE</medicinalproduct>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>STRENGTH:800 MG, DOSE : 3, 3X3</drugdosagetext>
        <drugdosageform>Film-coated tablet</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210727</drugstartdate>
        <activesubstance>
          <activesubstancename>SEVELAMER CARBONATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>SEMAGLUTIDE</medicinalproduct>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>STRENGTH: 1 MG, SOLUTION FOR INJECTION, SOLUTION IN PRE-FILLED INJECTION PEN, 1 MG/V, DOSE: 1</drugdosagetext>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210604</drugstartdate>
        <activesubstance>
          <activesubstancename>SEMAGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>SPIRONOLACTONE</medicinalproduct>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>STRENGTH:  25 MG, DOSE: 1, 0.5X1</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210722</drugstartdate>
        <activesubstance>
          <activesubstancename>SPIRONOLACTONE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211001</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>20035610</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211104</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220113</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-BEH-2021137866</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>28</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientagegroup>5</patientagegroup>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Injection site pain</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Recalled product administered</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Injection site erythema</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Recalled product administered</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Injection site swelling</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Recalled product administered</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Injection site swelling</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Injection site pruritus</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Injection site erythema</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HIZENTRA</medicinalproduct>
        <drugbatchnumb>P100320296</drugbatchnumb>
        <drugauthorizationnumb>125350</drugauthorizationnumb>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>002</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>10 GRAM, QW</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Immunodeficiency common variable</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210831</drugstartdate>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>HUMAN IMMUNOGLOBULIN G</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HIZENTRA</medicinalproduct>
        <drugbatchnumb>P100303965</drugbatchnumb>
        <drugauthorizationnumb>125350</drugauthorizationnumb>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>002</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>1 GRAM</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210831</drugstartdate>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>HUMAN IMMUNOGLOBULIN G</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HIZENTRA</medicinalproduct>
        <drugbatchnumb>P100340457</drugbatchnumb>
        <drugauthorizationnumb>125350</drugauthorizationnumb>
        <drugstructuredosagenumb>4</drugstructuredosagenumb>
        <drugstructuredosageunit>002</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>4 GRAM, QW</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210831</drugstartdate>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>HUMAN IMMUNOGLOBULIN G</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HIZENTRA</medicinalproduct>
        <drugbatchnumb>P100340460</drugbatchnumb>
        <drugauthorizationnumb>125350</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>HUMAN IMMUNOGLOBULIN G</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HIZENTRA</medicinalproduct>
        <drugauthorizationnumb>125350</drugauthorizationnumb>
        <drugstructuredosagenumb>15</drugstructuredosagenumb>
        <drugstructuredosageunit>002</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>15 GRAM, QW</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210818</drugstartdate>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>HUMAN IMMUNOGLOBULIN G</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211207</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20277081</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220102</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220102</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0261441</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Overdose</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DILAUDID</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>HYDROMORPHONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>4</safetyreportversion>
    <safetyreportid>19813763</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20210909</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220106</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>NVSC2021US202041</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>76</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Ageusia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Oedema peripheral</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Decreased appetite</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Nausea</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Dysphonia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TABRECTA</medicinalproduct>
        <drugbatchnumb>unknown</drugbatchnumb>
        <drugauthorizationnumb>213591</drugauthorizationnumb>
        <drugstructuredosagenumb>400</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>400 MG, BID</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Lung neoplasm malignant</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202104</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>CAPMATINIB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TABRECTA</medicinalproduct>
        <drugauthorizationnumb>213591</drugauthorizationnumb>
        <drugdosageform>Tablet</drugdosageform>
        <drugindication>Lung neoplasm malignant</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>CAPMATINIB</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20210902</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20321120</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedate>20220110</receivedate>
    <receiptdate>20220110</receiptdate>
    <fulfillexpeditecriteria>3</fulfillexpeditecriteria>
    <authoritynumb>FDA-CDER-CTU-2022-2475</authoritynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>59</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>COVID-19</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Intentional dose omission</reactionmeddrapt>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>XELJANZ XR</medicinalproduct>
        <drugbatchnumb>FA0918</drugbatchnumb>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>FREQUENCY : DAILY;?</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Psoriatic arthropathy</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201907</drugstartdate>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>TOFACITINIB CITRATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>XELJANZ XR</medicinalproduct>
        <drugindication>Psoriatic arthropathy</drugindication>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>TOFACITINIB CITRATE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>20172563</safetyreportid>
    <primarysourcecountry>DE</primarysourcecountry>
    <occurcountry>DE</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211211</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220120</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>DE-SAMSUNG BIOEPIS-SB-2021-28539</companynumb>
    <primarysource>
      <reportercountry>DE</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>49</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientagegroup>5</patientagegroup>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Acute myocardial infarction</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Endothelial dysfunction</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Angina pectoris</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>IMRALDI</medicinalproduct>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>2</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Rheumatoid arthritis</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ADALIMUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>VENLAFAXINE</medicinalproduct>
        <drugdosagetext>37.5-0-75 MG</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>VENLAFAXINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>AMLODIPINE</medicinalproduct>
        <drugdosagetext>2.5-0-2.5 MG</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>AMLODIPINE BESYLATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>RIZATRIPTAN</medicinalproduct>
        <drugdosagetext>ON DEMAND</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>RIZATRIPTAN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>METAMIZOLE</medicinalproduct>
        <drugstructuredosagenumb>500</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>THRICE, 500 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>METAMIZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TIZANIDINE</medicinalproduct>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>TIZANIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20210317</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20383749</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220127</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220127</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-ALLERGAN-2101595US</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug ineffective</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BOTOX COSMETIC</medicinalproduct>
        <drugbatchnumb>C6483</drugbatchnumb>
        <drugauthorizationnumb>1145103000</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>UNK, SINGLE</drugdosagetext>
        <drugdosageform>Powder for injection</drugdosageform>
        <drugindication>Skin wrinkling</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20201208</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20201208</drugenddate>
        <drugtreatmentduration>1</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ONABOTULINUMTOXINA</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BOTOX COSMETIC</medicinalproduct>
        <drugbatchnumb>C6651</drugbatchnumb>
        <drugauthorizationnumb>1145103000</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Powder for injection</drugdosageform>
        <drugindication>Skin wrinkling</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20201224</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20201224</drugenddate>
        <drugtreatmentduration>1</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ONABOTULINUMTOXINA</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20392622</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220128</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220128</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-CELGENE-USA-20220106715</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>2</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Joint swelling</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pollakiuria</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <drugbatchnumb>A3468A</drugbatchnumb>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>10 MILLIGRAM</drugdosagetext>
        <drugdosageform>Capsules</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Plasma cell myeloma</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20220104</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20371587</safetyreportid>
    <primarysourcecountry>MX</primarysourcecountry>
    <occurcountry>MX</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220124</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220124</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>MX-TAKEDA-2021TUS075467</companynumb>
    <primarysource>
      <reportercountry>MX</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>33</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Death</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Skin toxicity</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ICLUSIG</medicinalproduct>
        <drugauthorizationnumb>203469</drugauthorizationnumb>
        <drugstructuredosagenumb>45</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>45 MILLIGRAM</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Chronic myeloid leukaemia</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211004</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PONATINIB</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20220119</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20395633</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220130</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220130</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-NOVARTISPH-NVSC2022US019792</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>52</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Renal cancer</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Incorrect dose administered</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugauthorizationnumb>74467</drugauthorizationnumb>
        <drugstructuredosagenumb>150</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>150 MG,,DAILY,</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Gastrooesophageal reflux disease</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>200501</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201512</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugstructuredosagenumb>150</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>150 MG,,DAILY,</drugdosagetext>
        <drugdosageform>Capsule, hard</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Gastrooesophageal reflux disease</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>200501</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201512</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20150101</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20279657</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220103</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220103</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-144041</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>84</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Cerebrovascular accident</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ELIQUIS</medicinalproduct>
        <drugauthorizationnumb>202155</drugauthorizationnumb>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>5 MILLIGRAM, BID</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>APIXABAN</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20210401</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20354470</safetyreportid>
    <primarysourcecountry>GB</primarysourcecountry>
    <occurcountry>GB</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220120</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220120</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <authoritynumb>GB-MHRA-EYC 00271520</authoritynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>MHRA</duplicatesource>
      <duplicatenumb>GB-MHRA-ADR 26481484</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>GB</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>32</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>66</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Erythema</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Adverse drug reaction</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Insomnia</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Alopecia</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Weight decreased</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Adverse drug reaction</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Fatigue</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Adverse drug reaction</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Adverse drug reaction</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Adverse drug reaction</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Night sweats</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Lymphadenopathy</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Medication error</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ELOCON</medicinalproduct>
        <drugauthorizationnumb>19625</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Cream</drugdosageform>
        <drugadministrationroute>061</drugadministrationroute>
        <drugindication>Eczema</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20141010</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20190904</drugenddate>
        <drugtreatmentduration>1790</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>MOMETASONE FUROATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>EUMOVATE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>061</drugadministrationroute>
        <drugindication>Eczema</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20050512</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20190904</drugenddate>
        <drugtreatmentduration>5228</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>CLOBETASONE BUTYRATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HYDROCORTISONE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Cream</drugdosageform>
        <drugadministrationroute>061</drugadministrationroute>
        <drugindication>Eczema</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>19870308</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20190904</drugenddate>
        <drugtreatmentduration>11868</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>HYDROCORTISONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PREDNISONE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Ill-defined disorder</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20190201</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20190731</drugenddate>
        <drugtreatmentduration>180</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>PREDNISONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PROTOPIC</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>061</drugadministrationroute>
        <drugindication>Ill-defined disorder</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20190715</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20190815</drugenddate>
        <drugtreatmentduration>31</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>TACROLIMUS</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20170815</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20337029</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220114</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220114</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-BIOMARINAP-US-2022-140656</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>32</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>COVID-19</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PALYNZIQ</medicinalproduct>
        <drugbatchnumb>not reported</drugbatchnumb>
        <drugauthorizationnumb>761079</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>30, UNK, QD</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Phenylketonuria</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PEGVALIASE-PQPZ</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PALYNZIQ</medicinalproduct>
        <drugbatchnumb>not reported</drugbatchnumb>
        <drugauthorizationnumb>761079</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20180908</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PEGVALIASE-PQPZ</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20220104</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>5</safetyreportversion>
    <safetyreportid>14730003</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20180406</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220131</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-PFIZER INC-2018137218</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>Court case number</duplicatesource>
      <duplicatenumb>2:18-cv-04645</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>AstraZeneca</duplicatesource>
      <duplicatenumb>US-AstraZeneca-2018SE40583</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>Unknown</duplicatesource>
      <duplicatenumb>2:17-md-02789-CCC-M</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>Court case number</duplicatesource>
      <duplicatenumb>2:18-cv-04645-CCC-MF</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>TAKEDA</duplicatesource>
      <duplicatenumb>2018TUS010995</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>68</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>99.8</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Acute kidney injury</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Chronic kidney disease</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Renal pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PREVACID</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>200001</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201512</drugenddate>
        <drugtreatmentduration>5825</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>LANSOPRAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PROTONIX</medicinalproduct>
        <drugauthorizationnumb>20987</drugauthorizationnumb>
        <drugcumulativedosagenumb>5600</drugcumulativedosagenumb>
        <drugcumulativedosageunit>003</drugcumulativedosageunit>
        <drugdosagetext>UNK</drugdosagetext>
        <drugindication>Gastrooesophageal reflux disease</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>200001</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201512</drugenddate>
        <drugtreatmentduration>5825</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PANTOPRAZOLE SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PROTONIX</medicinalproduct>
        <drugauthorizationnumb>20987</drugauthorizationnumb>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugcumulativedosagenumb>5600</drugcumulativedosagenumb>
        <drugcumulativedosageunit>003</drugcumulativedosageunit>
        <drugdosagetext>40 MG, 2X/DAY</drugdosagetext>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20170113</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20170413</drugenddate>
        <drugtreatmentduration>91</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PANTOPRAZOLE SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DEXILANT</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>200001</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201512</drugenddate>
        <drugtreatmentduration>5825</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>DEXLANSOPRAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>NEXIUM</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>200001</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201512</drugenddate>
        <drugtreatmentduration>5825</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ESOMEPRAZOLE MAGNESIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>NEXIUM 24HR</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>200001</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201512</drugenddate>
        <drugtreatmentduration>5825</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ESOMEPRAZOLE MAGNESIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PREVACID 24 HR</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>200001</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201512</drugenddate>
        <drugtreatmentduration>5825</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>LANSOPRAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PRILOSEC</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Gastrooesophageal reflux disease</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>200001</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201512</drugenddate>
        <drugtreatmentduration>5825</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OMEPRAZOLE MAGNESIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PRILOSEC</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Gastrooesophageal reflux disease</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OMEPRAZOLE MAGNESIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PRILOSEC OTC</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Modified-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Gastrooesophageal reflux disease</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>200001</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201512</drugenddate>
        <drugtreatmentduration>5825</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OMEPRAZOLE MAGNESIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PRILOSEC OTC</medicinalproduct>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>20 MG, 1X/DAY</drugdosagetext>
        <drugdosageform>Modified-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2005</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2015</drugenddate>
        <drugtreatmentduration>3650</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OMEPRAZOLE MAGNESIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OMEPRAZOLE</medicinalproduct>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugcumulativedosagenumb>47200</drugcumulativedosagenumb>
        <drugcumulativedosageunit>003</drugcumulativedosageunit>
        <drugdosagetext>20 MG, 1X/DAY</drugdosagetext>
        <drugindication>Gastrooesophageal reflux disease</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20120524</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20120613</drugenddate>
        <drugtreatmentduration>43</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OMEPRAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OMEPRAZOLE</medicinalproduct>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugcumulativedosagenumb>47200</drugcumulativedosagenumb>
        <drugcumulativedosageunit>003</drugcumulativedosageunit>
        <drugdosagetext>40 MG, 1X/DAY</drugdosagetext>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20120614</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20120715</drugenddate>
        <drugtreatmentduration>32</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OMEPRAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OMEPRAZOLE</medicinalproduct>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugcumulativedosagenumb>47200</drugcumulativedosagenumb>
        <drugcumulativedosageunit>003</drugcumulativedosageunit>
        <drugdosagetext>20 MG, 1X/DAY</drugdosagetext>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20120705</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20160817</drugenddate>
        <drugtreatmentduration>1505</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OMEPRAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OMEPRAZOLE</medicinalproduct>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugcumulativedosagenumb>47200</drugcumulativedosagenumb>
        <drugcumulativedosageunit>003</drugcumulativedosageunit>
        <drugdosagetext>20 MG, 1X/DAY</drugdosagetext>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140124</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140424</drugenddate>
        <drugtreatmentduration>91</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OMEPRAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OMEPRAZOLE</medicinalproduct>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugcumulativedosagenumb>47200</drugcumulativedosagenumb>
        <drugcumulativedosageunit>003</drugcumulativedosageunit>
        <drugdosagetext>40 MG, 1X/DAY</drugdosagetext>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140425</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20160817</drugenddate>
        <drugtreatmentduration>846</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OMEPRAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OMEPRAZOLE</medicinalproduct>
        <drugcumulativedosagenumb>47200</drugcumulativedosagenumb>
        <drugcumulativedosageunit>003</drugcumulativedosageunit>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20160516</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OMEPRAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PANTOPRAZOLE</medicinalproduct>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>40 MG, 1X/DAY</drugdosagetext>
        <drugindication>Gastrooesophageal reflux disease</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20150907</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PANTOPRAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PANTOPRAZOLE</medicinalproduct>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>40 MG, 1X/DAY</drugdosagetext>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20160817</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20170218</drugenddate>
        <drugtreatmentduration>199</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PANTOPRAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PANTOPRAZOLE</medicinalproduct>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>40 MG, 1X/DAY</drugdosagetext>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20170308</drugstartdate>
        <drugtreatmentduration>199</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PANTOPRAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ATENOLOL</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Hypertension</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20120524</drugstartdate>
        <activesubstance>
          <activesubstancename>ATENOLOL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ATENOLOL</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 DF, 1X/DAY</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20141204</drugstartdate>
        <activesubstance>
          <activesubstancename>ATENOLOL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LISINOPRIL</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugindication>Hypertension</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20120524</drugstartdate>
        <activesubstance>
          <activesubstancename>LISINOPRIL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ULTRAM</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugindication>Osteoarthritis</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20130503</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2016</drugenddate>
        <drugtreatmentduration>1095</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <activesubstance>
          <activesubstancename>TRAMADOL HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ULTRAM</medicinalproduct>
        <drugindication>Pain</drugindication>
        <activesubstance>
          <activesubstancename>TRAMADOL HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FUROSEMIDE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugindication>Oedema</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140101</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140401</drugenddate>
        <drugtreatmentduration>91</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <activesubstance>
          <activesubstancename>FUROSEMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FUROSEMIDE</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 DF, 1X/DAY</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Oedema</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140101</drugstartdate>
        <activesubstance>
          <activesubstancename>FUROSEMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TRAMADOL HYDROCHLORIDE</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>TAKE ONE TABLET BY MOUTH EVERY 4 TO 6 HOURS AS NEEDED-TRAMADOL</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Pain</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140109</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140209</drugenddate>
        <drugtreatmentduration>32</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <activesubstance>
          <activesubstancename>TRAMADOL HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TRAMADOL HYDROCHLORIDE</medicinalproduct>
        <drugdosageform>Tablet</drugdosageform>
        <drugindication>Osteoarthritis</drugindication>
        <activesubstance>
          <activesubstancename>TRAMADOL HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CRESTOR</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugcumulativedosagenumb>32</drugcumulativedosagenumb>
        <drugcumulativedosageunit>032</drugcumulativedosageunit>
        <drugdosagetext>1 DF, 1X/DAY</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Blood cholesterol abnormal</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140124</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20140224</drugenddate>
        <drugtreatmentduration>32</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <activesubstance>
          <activesubstancename>ROSUVASTATIN CALCIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CRESTOR</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugindication>Blood cholesterol abnormal</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20150826</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2016</drugenddate>
        <activesubstance>
          <activesubstancename>ROSUVASTATIN CALCIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CRESTOR</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2017</drugstartdate>
        <activesubstance>
          <activesubstancename>ROSUVASTATIN CALCIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ATORVASTATIN</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugindication>Blood cholesterol abnormal</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20150827</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2016</drugenddate>
        <drugtreatmentduration>365</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <activesubstance>
          <activesubstancename>ATORVASTATIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ATORVASTATIN</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2017</drugstartdate>
        <activesubstance>
          <activesubstancename>ATORVASTATIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ROSUVASTATIN</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugindication>Blood cholesterol abnormal</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20150827</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2016</drugenddate>
        <activesubstance>
          <activesubstancename>ROSUVASTATIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ROSUVASTATIN</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2017</drugstartdate>
        <activesubstance>
          <activesubstancename>ROSUVASTATIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TYLENOL</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugindication>Pain</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2016</drugstartdate>
        <activesubstance>
          <activesubstancename>ACETAMINOPHEN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ZANTAC 150 (prescription)</medicinalproduct>
        <drugdosagetext>150 (PRESCRIPTION)</drugdosagetext>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2017</drugstartdate>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CLONIDINE</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 DF, 2X/DAY</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140101</drugstartdate>
        <activesubstance>
          <activesubstancename>CLONIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LEVOTHYROXINE</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 DF, 1X/DAY</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140101</drugstartdate>
        <activesubstance>
          <activesubstancename>LEVOTHYROXINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>KLOR-CON</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 DF, 1X/DAY</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140101</drugstartdate>
        <activesubstance>
          <activesubstancename>POTASSIUM CHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>SERTRALINE</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 DF, 1X/DAY</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140109</drugstartdate>
        <activesubstance>
          <activesubstancename>SERTRALINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>DIGOXIN</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 DF, 1X/DAY</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140109</drugstartdate>
        <activesubstance>
          <activesubstancename>DIGOXIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TIKOSYN</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 DF, 2X/DAY</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140124</drugstartdate>
        <activesubstance>
          <activesubstancename>DOFETILIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>AZITHROMYCIN</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20120923</drugstartdate>
        <activesubstance>
          <activesubstancename>AZITHROMYCIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PREDNISONE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20160104</drugstartdate>
        <activesubstance>
          <activesubstancename>PREDNISONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>GABAPENTIN</medicinalproduct>
        <drugdosageform>Capsule</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140318</drugstartdate>
        <activesubstance>
          <activesubstancename>GABAPENTIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>GABAPENTIN</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20160113</drugstartdate>
        <activesubstance>
          <activesubstancename>GABAPENTIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PRADAXA</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20140130</drugstartdate>
        <activesubstance>
          <activesubstancename>DABIGATRAN ETEXILATE MESYLATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>SERTRALINE HYDROCHLORIDE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20160113</drugstartdate>
        <activesubstance>
          <activesubstancename>SERTRALINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ROPINIROLE HYDROCHLORIDE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20160224</drugstartdate>
        <activesubstance>
          <activesubstancename>ROPINIROLE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>DILTIAZEM</medicinalproduct>
        <drugdosagetext>ER 24HR</drugdosagetext>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20150909</drugstartdate>
        <activesubstance>
          <activesubstancename>DILTIAZEM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>NITROGLYCERIN</medicinalproduct>
        <drugdosagetext>AS NEEDED PRN</drugdosagetext>
        <drugadministrationroute>060</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20150907</drugstartdate>
        <activesubstance>
          <activesubstancename>NITROGLYCERIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>MORPHINE</medicinalproduct>
        <drugdosagetext>2MG SYRINGE (MORPHINE) 4 MG = 2 ML INTRAVENOUS AS NEEDED PRN</drugdosagetext>
        <drugadministrationroute>042</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20150907</drugstartdate>
        <activesubstance>
          <activesubstancename>MORPHINE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20150907</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>5</safetyreportversion>
    <safetyreportid>20010686</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211028</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220127</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-110614</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>69</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>52</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Cerebrovascular accident</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>INVESTIGATIONAL PRODUCT</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugstructuredosagenumb>0.313</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>0.313 MILLIGRAM</drugdosagetext>
        <drugdosageform>Powder for solution for injection</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>Metastatic malignant melanoma</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210510</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211005</drugenddate>
        <drugtreatmentduration>149</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>INVESTIGATIONAL PRODUCT</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>NIVOLUMAB</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugauthorizationnumb>125554</drugauthorizationnumb>
        <drugstructuredosagenumb>360</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>360 MILLIGRAM</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>Metastatic malignant melanoma</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210510</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211005</drugenddate>
        <drugtreatmentduration>149</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>NIVOLUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TYLENOL</medicinalproduct>
        <drugstructuredosagenumb>650</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>650 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Pyrexia</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210512</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ACETAMINOPHEN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CALCIUM CARBONATE\CHOLECALCIFEROL</medicinalproduct>
        <drugstructuredosagenumb>600</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>600 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2012</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>CALCIUM CARBONATE\CHOLECALCIFEROL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>BENADRYL</medicinalproduct>
        <drugstructuredosagenumb>25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>25 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Rash erythematous</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210512</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>DIPHENHYDRAMINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>BENADRYL</medicinalproduct>
        <drugindication>Pruritus</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>DIPHENHYDRAMINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TRAMADOL</medicinalproduct>
        <drugstructuredosagenumb>50</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>50 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Musculoskeletal pain</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210517</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>TRAMADOL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ONDANSETRON</medicinalproduct>
        <drugstructuredosagenumb>8</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>8 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Nausea</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210512</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ONDANSETRON</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>COMPAZINE</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>10 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Nausea</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210512</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PROCHLORPERAZINE MALEATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>VAGISIL MEDICATED CREAM</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>1 DOSAGE FORM = 1 UNIT NOS</drugdosagetext>
        <drugdosageform>Cream</drugdosageform>
        <drugadministrationroute>067</drugadministrationroute>
        <drugindication>Vulvovaginal pruritus</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210517</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>DIPHENHYDRAMINE</medicinalproduct>
        <drugstructuredosagenumb>25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>25 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210601</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>DIPHENHYDRAMINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ESTRADIOL</medicinalproduct>
        <drugstructuredosagenumb>0.1</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>0.1 MILLIGRAM</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>067</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2013</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ESTRADIOL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ESTRADIOL</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>1 DOSAGE FORM = 10 UNIT NOS</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>067</drugadministrationroute>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2020</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ESTRADIOL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>IBUPROFEN</medicinalproduct>
        <drugstructuredosagenumb>800</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>800 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Musculoskeletal pain</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2017</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>IBUPROFEN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>IBUPROFEN</medicinalproduct>
        <drugstructuredosagenumb>800</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>800 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Non-cardiac chest pain</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210512</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>IBUPROFEN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>IBUPROFEN</medicinalproduct>
        <drugstructuredosagenumb>600</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>600 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Pyrexia</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211016</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>IBUPROFEN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>IBUPROFEN</medicinalproduct>
        <drugindication>Inflammation</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>IBUPROFEN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>VITAMINS NOS</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>1 DOSAGE FORM = 1 UNIT NOS</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2013</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>VITAMINS</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>SENNOSIDES</medicinalproduct>
        <drugstructuredosagenumb>8.6</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>8.6 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210608</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>SENNOSIDES</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>COLACE</medicinalproduct>
        <drugstructuredosagenumb>100</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>100 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210608</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>DOCUSATE SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>MIRALAX</medicinalproduct>
        <drugstructuredosagenumb>17</drugstructuredosagenumb>
        <drugstructuredosageunit>002</drugstructuredosageunit>
        <drugdosagetext>17 GRAM</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Constipation</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210608</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>POLYETHYLENE GLYCOL 3350</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>OMEPRAZOLE</medicinalproduct>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>20 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Abdominal discomfort</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210720</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OMEPRAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LATANOPROST</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>1 DOSAGE FORM = 0.005 UNIT NOS</drugdosagetext>
        <drugdosageform>Eye drops</drugdosageform>
        <drugadministrationroute>047</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2014</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>LATANOPROST</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>COMBIGAN</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>1 DOSAGE FORM  = 0.2 UNIT NOS</drugdosagetext>
        <drugdosageform>Eye drops</drugdosageform>
        <drugadministrationroute>047</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2014</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>BRIMONIDINE TARTRATE\TIMOLOL MALEATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PROLIA</medicinalproduct>
        <drugstructuredosagenumb>60</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>60 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210114</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>DENOSUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CLARITHROMYCIN</medicinalproduct>
        <drugstructuredosagenumb>100</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>100 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2014</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>CLARITHROMYCIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ZOLPIDEM</medicinalproduct>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>5 MILLIGRAM</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2020</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ZOLPIDEM TARTRATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>MODERNA COVID-19 VACCINE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>030</drugadministrationroute>
        <drugindication>Prophylaxis</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211015</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ELASOMERAN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FLU SYRINGE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>030</drugadministrationroute>
        <drugindication>Prophylaxis</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211015</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>DICLOFENAC</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Gel</drugdosageform>
        <drugadministrationroute>061</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>DICLOFENAC</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211020</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20386506</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220127</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220127</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-ALLERGAN-2143369US</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Off label use</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Multiple use of single-use product</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Product preparation error</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Wrong technique in product usage process</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Therapeutic response decreased</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Therapeutic response shortened</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BOTOX COSMETIC</medicinalproduct>
        <drugbatchnumb>C6978</drugbatchnumb>
        <drugauthorizationnumb>1145103000</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>30 UNITS, SINGLE</drugdosagetext>
        <drugdosageform>Powder for injection</drugdosageform>
        <drugindication>Skin wrinkling</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211021</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211021</drugenddate>
        <drugtreatmentduration>1</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ONABOTULINUMTOXINA</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20301996</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220105</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220105</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-ABBVIE-21K-163-3874738-00</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Cough</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>VENCLEXTA</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugauthorizationnumb>208573</drugauthorizationnumb>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>VENETOCLAX</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20366756</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>3</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220123</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220123</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-ACORDA-ACO_170682_2021</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug ineffective</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>AMPYRA</medicinalproduct>
        <drugauthorizationnumb>22250</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20201001</drugstartdate>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>DALFAMPRIDINE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20291904</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220104</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220104</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-GALDERMA-US2021018966</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Skin irritation</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Erythema</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Condition aggravated</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PROACTIV MD ADAPALENE ACNE TREATMENT</medicinalproduct>
        <drugauthorizationnumb>20380</drugauthorizationnumb>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugcumulativedosagenumb>7</drugcumulativedosagenumb>
        <drugcumulativedosageunit>032</drugcumulativedosageunit>
        <drugdosagetext>1 DOSAGE FORM, QD, DAILY</drugdosagetext>
        <drugdosageform>Gel</drugdosageform>
        <drugadministrationroute>061</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211001</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211101</drugenddate>
        <drugtreatmentduration>1</drugtreatmentduration>
        <drugtreatmentdurationunit>802</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>ADAPALENE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Proactiv MD Ultra Gentle Cleanser</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>1 DOSAGE FORM, QD, DAILY</drugdosagetext>
        <drugdosageform>Cutaneous solution</drugdosageform>
        <drugadministrationroute>061</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211001</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211101</drugenddate>
        <drugtreatmentduration>1</drugtreatmentduration>
        <drugtreatmentdurationunit>802</drugtreatmentdurationunit>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Proactiv MD Ultra Hydrating Moisturizer</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>1 DOSAGE FORM, QD, DAILY</drugdosagetext>
        <drugdosageform>Cutaneous solution</drugdosageform>
        <drugadministrationroute>061</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211001</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211101</drugenddate>
        <drugtreatmentduration>1</drugtreatmentduration>
        <drugtreatmentdurationunit>802</drugtreatmentdurationunit>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211008</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20320160</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220111</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220111</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-APOTEX-2022AP001829</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
      <literaturereference>Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Bronstein AC, Rivers LJ, Pham NPT, Weber J. 2020 Annual Report of the American Association of Poison Control Centers^ National Poison Data System (NPDS): 38th Annual Report. Clinical Toxicology. 2021;59 (12):1282?1501</literaturereference>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>69</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Completed suicide</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Cardio-respiratory arrest</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ZOLPIDEM</medicinalproduct>
        <drugauthorizationnumb>077884</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ZOLPIDEM TARTRATE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20200101</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>20058331</safetyreportid>
    <primarysourcecountry>CA</primarysourcecountry>
    <occurcountry>CA</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211111</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220106</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>CA-TAKEDA-2021TUS030832</companynumb>
    <primarysource>
      <reportercountry>CA</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>56</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Colitis ulcerative</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Diarrhoea</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Anxiety</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>VEDOLIZUMAB</medicinalproduct>
        <drugbatchnumb>11981132</drugbatchnumb>
        <drugauthorizationnumb>125476</drugauthorizationnumb>
        <drugstructuredosagenumb>300</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>300 MILLIGRAM</drugdosagetext>
        <drugdosageform>Powder for solution for infusion</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>Colitis ulcerative</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210201</drugstartdate>
        <actiondrug>1</actiondrug>
        <drugadditional>2</drugadditional>
        <activesubstance>
          <activesubstancename>VEDOLIZUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>VEDOLIZUMAB</medicinalproduct>
        <drugbatchnumb>12090694</drugbatchnumb>
        <drugauthorizationnumb>125476</drugauthorizationnumb>
        <drugstructuredosagenumb>300</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>300 MILLIGRAM</drugdosagetext>
        <drugdosageform>Powder for solution for infusion</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20211108</drugenddate>
        <actiondrug>1</actiondrug>
        <drugadditional>2</drugadditional>
        <activesubstance>
          <activesubstancename>VEDOLIZUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PREDNISONE</medicinalproduct>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>40 MILLIGRAM</drugdosagetext>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210112</drugstartdate>
        <activesubstance>
          <activesubstancename>PREDNISONE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20341155</safetyreportid>
    <primarysourcecountry>GB</primarysourcecountry>
    <occurcountry>GB</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220117</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220117</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <authoritynumb>GB-MHRA-EYC 00271175</authoritynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>MHRA</duplicatesource>
      <duplicatenumb>GB-MHRA-ADR 26466139</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>GB</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>38</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Adverse drug reaction</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MOMETASONE FUROATE</medicinalproduct>
        <drugauthorizationnumb>77061</drugauthorizationnumb>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>ONE SPRAY THROUGH BOTH NOSTRILS TWICE A DAY  50 MICROGRAMS</drugdosagetext>
        <drugdosageform>Nasal spray, suspension</drugdosageform>
        <drugadministrationroute>045</drugadministrationroute>
        <drugindication>Ill-defined disorder</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20220112</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20220112</drugenddate>
        <drugtreatmentduration>1</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>MOMETASONE FUROATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>SERTRALINE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Ill-defined disorder</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>SERTRALINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PENICILLIN V</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Ill-defined disorder</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PENICILLIN V</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20220112</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20283391</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>1</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220103</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220103</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0267731</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DILAUDID</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>HYDROMORPHONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>18838188</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20210203</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220127</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-ALLERGAN-2048162US</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>55</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Periorbital swelling</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BOTOX COSMETIC</medicinalproduct>
        <drugauthorizationnumb>1145103000</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>16 UNITS, SINGLE</drugdosagetext>
        <drugdosageform>Powder for injection</drugdosageform>
        <drugindication>Skin wrinkling</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ONABOTULINUMTOXINA</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BOTOX COSMETIC</medicinalproduct>
        <drugauthorizationnumb>1145103000</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>16 UNITS, SINGLE</drugdosagetext>
        <drugdosageform>Powder for injection</drugdosageform>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ONABOTULINUMTOXINA</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>3</safetyreportversion>
    <safetyreportid>20131741</safetyreportid>
    <primarysourcecountry>AU</primarysourcecountry>
    <occurcountry>AU</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211130</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220117</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>AU-ALXN-A202112815</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>ALXN</duplicatesource>
      <duplicatenumb>AU-ALXN-A202112900</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>AU</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Atypical haemolytic uraemic syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug ineffective</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SOLIRIS</medicinalproduct>
        <drugauthorizationnumb>125166</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Concentrate for solution for infusion</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Atypical haemolytic uraemic syndrome</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ECULIZUMAB</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>20236370</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211228</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220118</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-BIOGEN-2021BI01081266</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>46</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Agitation</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Depression</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PLEGRIDY</medicinalproduct>
        <drugbatchnumb>SH0463</drugbatchnumb>
        <drugauthorizationnumb>125499</drugauthorizationnumb>
        <drugstructuredosagenumb>63</drugstructuredosagenumb>
        <drugstructuredosageunit>004</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>14</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosageform>Solution for injection in pre-filled pen</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Multiple sclerosis</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210921</drugstartdate>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>PEGINTERFERON BETA-1A</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PLEGRIDY</medicinalproduct>
        <drugbatchnumb>SH0463</drugbatchnumb>
        <drugauthorizationnumb>125499</drugauthorizationnumb>
        <drugstructuredosagenumb>125</drugstructuredosagenumb>
        <drugstructuredosageunit>004</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>14</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosageform>Solution for injection in pre-filled pen</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211019</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>202111</drugenddate>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>PEGINTERFERON BETA-1A</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>AMBIEN</medicinalproduct>
        <drugdosageform>Unknown</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <activesubstance>
          <activesubstancename>ZOLPIDEM TARTRATE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211001</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20404343</safetyreportid>
    <primarysourcecountry>GR</primarysourcecountry>
    <occurcountry>GR</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220131</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220131</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>GR-RISINGPHARMA-GR-2022RISLIT00063</companynumb>
    <primarysource>
      <reportercountry>GR</reportercountry>
      <qualification>3</qualification>
      <literaturereference>Panagiotis N Margos.Digitalis-related electric storm short after ICD implantation.Hellenic Journal of Cardiology.30-JUL-2020;62:480-484</literaturereference>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>66</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientagegroup>5</patientagegroup>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Arrhythmic storm</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Extrasystoles</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Bradycardia</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Toxicity to various agents</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DIGITEK</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>040282</drugauthorizationnumb>
        <drugstructuredosagenumb>0.5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosageform>TAB</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Atrial fibrillation</drugindication>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>DIGOXIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>RAMIPRIL</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugstructuredosagenumb>2.5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>RAMIPRIL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FUROSEMIDE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>FUROSEMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>EPLERENONE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugstructuredosagenumb>25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>EPLERENONE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20273306</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>1</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220101</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220101</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0244488</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DILAUDID</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>HYDROMORPHONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20380799</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220127</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220127</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-SA-SAC20220124000899</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>SA</duplicatesource>
      <duplicatenumb>US-SA-SAC20220124000899</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>PORTAL ID</duplicatesource>
      <duplicatenumb>SanofiPVPortal20220119001107</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>19</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientagegroup>5</patientagegroup>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Product dose omission issue</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CERDELGA</medicinalproduct>
        <drugauthorizationnumb>205494</drugauthorizationnumb>
        <drugstructuredosagenumb>84</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosagetext>84 MG, BID</drugdosagetext>
        <drugdosageform>Capsule, hard</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Gaucher^s disease</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20200519</drugstartdate>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ELIGLUSTAT</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20220117</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>20126944</safetyreportid>
    <primarysourcecountry>PL</primarysourcecountry>
    <occurcountry>PL</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211129</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220105</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>PL-Zentiva-2021-ZT-005385</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>e-PL</duplicatesource>
      <duplicatenumb>Case-PL-20210921-122115_0</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>EMA</duplicatesource>
      <duplicatenumb>PL-EMA-DD-20211217-kakwani_d-130744</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>TEVA</duplicatesource>
      <duplicatenumb>PL-TEVA-2021-PL-1926070</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>2021</duplicatesource>
      <duplicatenumb>BL-2021-017758</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>2021</duplicatesource>
      <duplicatenumb>BL-2021-027106</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>GLAXOSMITHKLINE</duplicatesource>
      <duplicatenumb>PL-GLAXOSMITHKLINE-PLCH2021EME048493</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>Gedeon Richter Plc.</duplicatesource>
      <duplicatenumb>PL-Gedeon Richter Plc.-2021_GR_007325</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>Case identifiers</duplicatesource>
      <duplicatenumb>10009858231</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>Case identifiers</duplicatesource>
      <duplicatenumb>10010145574</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>Case identifiers</duplicatesource>
      <duplicatenumb>10010545420</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>GLAXOSMITHKLINE</duplicatesource>
      <duplicatenumb>PL-GLAXOSMITHKLINE-PLCH2021EME074701</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>Zentiva</duplicatesource>
      <duplicatenumb>PL-Zentiva-2021-ZT-005385</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>PL</reportercountry>
      <qualification>1</qualification>
      <literaturereference>Grabysa M, Tomaszewska A, Grabysa R. Metoprolol as a universal b-blocker: sample clinical scenarios. Clinical pharmacology in practice. 2020;14, 3-4:26-33</literaturereference>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>69</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>99</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Bradycardia</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Hypotension</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Atrial fibrillation</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Myocardial ischaemia</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Cough</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Heart rate decreased</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Blood pressure decreased</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PERINDOPRIL</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>PERINDOPRIL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PERINDOPRIL</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 DOSAGE FORM, QD (1 DF, QD)</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>PERINDOPRIL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>METFORMIN</medicinalproduct>
        <drugauthorizationnumb>075973</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>METFORMIN HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>METFORMIN</medicinalproduct>
        <drugauthorizationnumb>075973</drugauthorizationnumb>
        <drugstructuredosagenumb>1000</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>100 MILLIGRAM, QD (1000 MG, QD)</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>METFORMIN HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ATORVASTATIN</medicinalproduct>
        <drugauthorizationnumb>091226</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>ATORVASTATIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ATORVASTATIN</medicinalproduct>
        <drugauthorizationnumb>091226</drugauthorizationnumb>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>20 MILLIGRAM, QD</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>ATORVASTATIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BISOPROLOL</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>BISOPROLOL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BISOPROLOL</medicinalproduct>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>5 MILLIGRAM, QD (5 MG, QD)</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>BISOPROLOL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ASPIRIN</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>ASPIRIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ASPIRIN</medicinalproduct>
        <drugstructuredosagenumb>1800</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1800 MILLIGRAM, QD (75 MG, 24D)</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>ASPIRIN</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20272633</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>1</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220101</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220101</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0253435</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20324062</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220111</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220111</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-MYLANLABS-2022M1001815</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Seizure</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PHENYTOIN</medicinalproduct>
        <drugauthorizationnumb>040298</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PHENYTOIN</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20316118</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220110</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220110</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-AUROBINDO-AUR-APL-2021-011595</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatenumb>ADE2021-0343</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatenumb>21/1362</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>72</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>74</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Myalgia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Accidental overdose</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>FEXOFENADINE HYDROCHLORIDE</medicinalproduct>
        <drugbatchnumb>79T000920A</drugbatchnumb>
        <drugauthorizationnumb>202039</drugauthorizationnumb>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosagetext>1 DOSAGE FORM, DAILY</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Hypersensitivity</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>FEXOFENADINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SIMVASTATIN</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>SIMVASTATIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LOSARTAN</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>LOSARTAN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>VITAMIN D3</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>CHOLECALCIFEROL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TYLENOL</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ACETAMINOPHEN</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20407631</safetyreportid>
    <primarysourcecountry>IL</primarysourcecountry>
    <occurcountry>IL</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220131</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220131</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>IL-SA-SAC20220129000036</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>SA</duplicatesource>
      <duplicatenumb>IL-SA-2022SA028499</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatenumb>SanofiPVPortal20220126000580</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>SA</duplicatesource>
      <duplicatenumb>IL-SA-SAC20220129000036</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>IL</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Death</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LIBTAYO</medicinalproduct>
        <drugauthorizationnumb>761097</drugauthorizationnumb>
        <drugdosageform>Injection</drugdosageform>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>CEMIPLIMAB-RWLC</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>4</safetyreportversion>
    <safetyreportid>19924952</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211006</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220122</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>NVSC2021US227855</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Skin lesion</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Therapeutic product effect incomplete</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>COSENTYX</medicinalproduct>
        <drugauthorizationnumb>125504</drugauthorizationnumb>
        <drugstructuredosagenumb>300</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>300 MG, QW (FOR 5 WEEKS)</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Psoriatic arthropathy</drugindication>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>SECUKINUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>COSENTYX</medicinalproduct>
        <drugauthorizationnumb>125504</drugauthorizationnumb>
        <drugstructuredosagenumb>300</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>802</drugintervaldosagedefinition>
        <drugdosagetext>300 MG, QMO</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Psoriasis</drugindication>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>SECUKINUMAB</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20332333</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220113</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220113</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-SUNOVION-2021SUN004789</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Depression</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Therapy interrupted</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LATUDA</medicinalproduct>
        <drugauthorizationnumb>200603</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>LURASIDONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>QUETIAPINE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>QUETIAPINE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>20323284</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220111</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220111</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-NOVOPROD-840774</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>2</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientagegroup>5</patientagegroup>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Taste disorder</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RYBELSUS</medicinalproduct>
        <drugstructuredosagenumb>7</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>7 MG, QD</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Type 2 diabetes mellitus</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2021</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>SEMAGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RYBELSUS</medicinalproduct>
        <drugauthorizationnumb>213051</drugauthorizationnumb>
        <drugstructuredosagenumb>3</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>3 MG, QD</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Type 2 diabetes mellitus</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202106</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2021</drugenddate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>SEMAGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20210601</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20269980</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220101</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220101</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0256651</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DILAUDID</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>HYDROMORPHONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MS CONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MORPHINE SULFATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HYSINGLA ER</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>HYDROCODONE BITARTRATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCODONE HYDROCHLORIDE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RYZOLT</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>TRAMADOL HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20338153</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220115</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220115</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-SA-SAC20220111000642</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>SA</duplicatesource>
      <duplicatenumb>US-SA-SAC20220111000642</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>PORTAL ID</duplicatesource>
      <duplicatenumb>SanofiPVPortal20220107000313</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>37</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientagegroup>5</patientagegroup>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>COVID-19</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>SARS-CoV-2 test positive</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>FABRAZYME</medicinalproduct>
        <drugauthorizationnumb>103979</drugauthorizationnumb>
        <drugstructuredosagenumb>70</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>2</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>70 MG, QOW</drugdosagetext>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>Fabry^s disease</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20200409</drugstartdate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>AGALSIDASE BETA</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>FABRAZYME</medicinalproduct>
        <drugauthorizationnumb>103979</drugauthorizationnumb>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>2</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>10 MG, QOW</drugdosagetext>
        <drugadministrationroute>042</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20200409</drugstartdate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>AGALSIDASE BETA</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211214</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>18265723</safetyreportid>
    <primarysourcecountry>CA</primarysourcecountry>
    <occurcountry>CA</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20200915</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220113</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>CA-BAUSCH-BL-2020-025875</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>Health Canada</duplicatesource>
      <duplicatenumb>E2B_03193921</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>Market Authorization Holder AER Number</duplicatesource>
      <duplicatenumb>2020147397</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>Duplicate case ID</duplicatesource>
      <duplicatenumb>BL-2020-026588</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>Duplicate case ID</duplicatesource>
      <duplicatenumb>E2B_03170465</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>Duplicate case ID</duplicatesource>
      <duplicatenumb>BL-2021-018704</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>Duplicate case ID</duplicatesource>
      <duplicatenumb>E2B_03725133</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>Duplicate case ID</duplicatesource>
      <duplicatenumb>2020SA105416AA</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>Duplicate case ID</duplicatesource>
      <duplicatenumb>BL-2021-031194</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>Duplicate case ID</duplicatesource>
      <duplicatenumb>2002CAN010574</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>Duplicate case ID</duplicatesource>
      <duplicatenumb>E2B_04137972</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>CA</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>61</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Appetite disorder</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Asthma</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Chest discomfort</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Chest pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Cough</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Depressive symptom</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Fall</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Flank pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Heart sounds</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Influenza</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Injury</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Loss of personal independence in daily activities</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Lower respiratory tract infection</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Productive cough</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Prolonged expiration</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pyrexia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Rales</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Respiration abnormal</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Rhinorrhoea</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Sleep disorder due to a general medical condition</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Stress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Weight decreased</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Wheezing</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Nasopharyngitis</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Nasal congestion</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Upper respiratory tract infection</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Malaise</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Angina pectoris</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Depressed mood</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Dyspnoea</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Dyspnoea exertional</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Insomnia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DILTIAZEM HYDROCHLORIDE</medicinalproduct>
        <drugauthorizationnumb>18602</drugauthorizationnumb>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugtreatmentduration>14</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>DILTIAZEM HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>METFORMIN HYDROCHLORIDE</medicinalproduct>
        <drugauthorizationnumb>21748</drugauthorizationnumb>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>METFORMIN HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>NITROGLYCERIN</medicinalproduct>
        <drugauthorizationnumb>89771</drugauthorizationnumb>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>NITROGLYCERIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ALBUTEROL</medicinalproduct>
        <drugauthorizationnumb>75358</drugauthorizationnumb>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ALBUTEROL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ALBUTEROL SULFATE</medicinalproduct>
        <drugauthorizationnumb>75358</drugauthorizationnumb>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ALBUTEROL SULFATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>THEOPHYLLINE</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>THEOPHYLLINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LOPERAMIDE HYDROCHLORIDE</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>LOPERAMIDE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BETAMETHASONE VALERATE</medicinalproduct>
        <drugdosageform>Ointment</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Eczema</drugindication>
        <drugtreatmentduration>30</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>BETAMETHASONE VALERATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ADVAIR HFA</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugtreatmentduration>30</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>FLUTICASONE PROPIONATE\SALMETEROL XINAFOATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ADVAIR HFA</medicinalproduct>
        <drugstructuredosagenumb>2</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosagetext>ROUTE: INHALATION</drugdosagetext>
        <drugadministrationroute>050</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>FLUTICASONE PROPIONATE\SALMETEROL XINAFOATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ACETAMINOPHEN</medicinalproduct>
        <drugstructuredosagenumb>2</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ACETAMINOPHEN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>AMITRIPTYLINE HYDROCHLORIDE</medicinalproduct>
        <drugstructuredosagenumb>4</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>24</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>AMITRIPTYLINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ATORVASTATIN</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>24</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ATORVASTATIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PREDNISONE</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>24</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PREDNISONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PREDNISONE</medicinalproduct>
        <drugstructuredosagenumb>4</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>24</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PREDNISONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PREDNISONE</medicinalproduct>
        <drugstructuredosagenumb>3</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>24</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PREDNISONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PREDNISONE</medicinalproduct>
        <drugstructuredosagenumb>2</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>24</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PREDNISONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ATROVENT</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>IPRATROPIUM BROMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>AZITHROMYCIN</medicinalproduct>
        <drugstructuredosagenumb>3</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>AZITHROMYCIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>COMBIVENT</medicinalproduct>
        <drugdosagetext>SOLUTION FOR INHALATION</drugdosagetext>
        <drugdosageform>Solution</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ALBUTEROL SULFATE\IPRATROPIUM BROMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PINAVERIUM BROMIDE</medicinalproduct>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PINAVERIUM BROMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DIMENHYDRINATE</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>DIMENHYDRINATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>FLUOXETINE HYDROCHLORIDE</medicinalproduct>
        <drugstructuredosagenumb>2</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugtreatmentduration>14</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>FLUOXETINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>FLOVENT</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>FLUTICASONE PROPIONATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>FUROSEMIDE</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>FUROSEMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LACTASE</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>8</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>LACTASE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MEPOLIZUMAB</medicinalproduct>
        <drugstructuredosagenumb>100</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Asthma</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MEPOLIZUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MOMETASONE FUROATE</medicinalproduct>
        <drugstructuredosagenumb>2</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MOMETASONE FUROATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MONTELUKAST</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>24</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MONTELUKAST SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>NOVORAPID</medicinalproduct>
        <drugstructuredosagenumb>3</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>24</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosagetext>SOLUTION SUBCUTANEOUS</drugdosagetext>
        <drugdosageform>Solution</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugtreatmentduration>84</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>INSULIN ASPART</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>NITROFURANTOIN</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>24</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosageform>Capsule</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>NITROFURANTOIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PREDNISONE</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PREDNISONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>QUINAPRIL HYDROCHLORIDE</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>24</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>QUINAPRIL HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LACTULOSE</medicinalproduct>
        <drugstructuredosagenumb>1.5</drugstructuredosagenumb>
        <drugstructuredosageunit>012</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosageform>Oral solution</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>LACTULOSE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>GLYCOPYRROLATE</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>24</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosageform>Capsule</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugtreatmentduration>30</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>GLYCOPYRROLATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SEMAGLUTIDE</medicinalproduct>
        <drugstructuredosagenumb>1.25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>SOLUTION SUBCUTANEOUS</drugdosagetext>
        <drugdosageform>Solution</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>SEMAGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SINGULAIR</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MONTELUKAST SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SPIRIVA RESPIMAT</medicinalproduct>
        <drugdosagetext>FOR ORAL INHALATION WITH RESPIMAT INHALER ONLY 0.5 G/DOSE</drugdosagetext>
        <drugdosageform>Solution</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>TIOTROPIUM BROMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TRESIBA</medicinalproduct>
        <drugstructuredosagenumb>50</drugstructuredosagenumb>
        <drugstructuredosageunit>025</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>24</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>INSULIN DEGLUDEC</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>UNIPHYL</medicinalproduct>
        <drugdosagetext>EXTEND-EDRELEASE</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>THEOPHYLLINE ANHYDROUS</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>VITAMIN B12</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>012</drugstructuredosageunit>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>CYANOCOBALAMIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DIBUCAINE HYDROCHLORIDE</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>DIBUCAINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ESCULIN</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ESCULIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>FLUTICASONE PROPIONATE\SALMETEROL XINAFOATE</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugtreatmentduration>30</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>FLUTICASONE PROPIONATE\SALMETEROL XINAFOATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>FLUTICASONE PROPIONATE\SALMETEROL XINAFOATE</medicinalproduct>
        <drugstructuredosagenumb>2</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugadministrationroute>055</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>FLUTICASONE PROPIONATE\SALMETEROL XINAFOATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>INSULIN ASPART</medicinalproduct>
        <drugstructuredosagenumb>3</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugtreatmentduration>84</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>INSULIN ASPART</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MONTELUKAST SODIUM</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugtreatmentduration>14</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MONTELUKAST SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PEDIAPRED</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PREDNISOLONE SODIUM PHOSPHATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PEDIAPRED</medicinalproduct>
        <drugstructuredosagenumb>2</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PREDNISOLONE SODIUM PHOSPHATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PEDIAPRED</medicinalproduct>
        <drugstructuredosagenumb>3</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PREDNISOLONE SODIUM PHOSPHATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PEDIAPRED</medicinalproduct>
        <drugstructuredosagenumb>4</drugstructuredosagenumb>
        <drugstructuredosageunit>032</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PREDNISOLONE SODIUM PHOSPHATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PEDIAPRED</medicinalproduct>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PREDNISOLONE SODIUM PHOSPHATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PINAVERIUM BROMIDE</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugtreatmentduration>14</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>PINAVERIUM BROMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TIOTROPIUM BROMIDE</medicinalproduct>
        <drugadministrationroute>055</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugtreatmentduration>14</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>TIOTROPIUM BROMIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20356459</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedate>20220119</receivedate>
    <receiptdate>20220119</receiptdate>
    <fulfillexpeditecriteria>3</fulfillexpeditecriteria>
    <authoritynumb>FDA-CDER-CTU-2022-5241</authoritynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>36</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>57.61</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Oral mucosal blistering</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Oral mucosal erythema</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Purulence</reactionmeddrapt>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>GAMUNEX-C</medicinalproduct>
        <drugrecurreadministration>1</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>HUMAN IMMUNOGLOBULIN G</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>MAPAP 500mg Oral</medicinalproduct>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Diphenhydramine 25mg Oral</medicinalproduct>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20220114</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20278487</safetyreportid>
    <primarysourcecountry>IL</primarysourcecountry>
    <occurcountry>IL</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220103</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220103</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>IL-BAYER-2021A275734</companynumb>
    <primarysource>
      <reportercountry>IL</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>86</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientagegroup>6</patientagegroup>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Asthenia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Dyspnoea</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Melaena</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Haemoglobin decreased</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>XARELTO</medicinalproduct>
        <drugauthorizationnumb>202439</drugauthorizationnumb>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>20 MG, QD</drugdosagetext>
        <drugdosageform>Film-coated tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Atrial fibrillation</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201606</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>RIVAROXABAN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>BISOPROLOL FUMARATE</medicinalproduct>
        <activesubstance>
          <activesubstancename>BISOPROLOL FUMARATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>COSOPT</medicinalproduct>
        <activesubstance>
          <activesubstancename>DORZOLAMIDE HYDROCHLORIDE\TIMOLOL MALEATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FUROSEMIDE</medicinalproduct>
        <drugdosageform>Powder for infusion</drugdosageform>
        <activesubstance>
          <activesubstancename>FUROSEMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FOLIC ACID</medicinalproduct>
        <drugdosageform>Tablet</drugdosageform>
        <activesubstance>
          <activesubstancename>FOLIC ACID</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>NITROLINGUAL</medicinalproduct>
        <activesubstance>
          <activesubstancename>NITROGLYCERIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>OMEPRAZOLE</medicinalproduct>
        <activesubstance>
          <activesubstancename>OMEPRAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>RAMIPRIL</medicinalproduct>
        <activesubstance>
          <activesubstancename>RAMIPRIL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>SPIRONOLACTONE</medicinalproduct>
        <activesubstance>
          <activesubstancename>SPIRONOLACTONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LIPTOR [ATORVASTATIN CALCIUM]</medicinalproduct>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211201</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20391889</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedate>20220128</receivedate>
    <receiptdate>20220128</receiptdate>
    <fulfillexpeditecriteria>3</fulfillexpeditecriteria>
    <authoritynumb>FDA-CDER-CTU-2022-7893</authoritynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug hypersensitivity</reactionmeddrapt>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ENBREL</medicinalproduct>
        <drugstructuredosagenumb>50</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>FREQUENCY : WEEKLY;?</drugdosagetext>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Rheumatoid arthritis</drugindication>
        <activesubstance>
          <activesubstancename>ETANERCEPT</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>14</safetyreportversion>
    <safetyreportid>14985159</safetyreportid>
    <primarysourcecountry>CA</primarysourcecountry>
    <occurcountry>CA</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20180607</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220112</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>PHHY2018CA014967</companynumb>
    <primarysource>
      <reportercountry>CA</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>62</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Hepatic vein thrombosis</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Wound</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Erythema</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Hepatic lesion</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Malignant neoplasm progression</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Carcinoid tumour</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Breast mass</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Sinus pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Blood pressure increased</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Back pain</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Ligament sprain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Arthralgia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Musculoskeletal pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain in extremity</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Dizziness</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Headache</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Injection site pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Syringe issue</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Inappropriate schedule of product administration</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SANDOSTATIN LAR DEPOT</medicinalproduct>
        <drugauthorizationnumb>21008</drugauthorizationnumb>
        <drugstructuredosagenumb>30</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>4</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>30 MG, Q4W (EVERY 4 WEEKS)</drugdosagetext>
        <drugadministrationroute>030</drugadministrationroute>
        <drugindication>Carcinoid tumour</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20180507</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OCTREOTIDE ACETATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SANDOSTATIN LAR DEPOT</medicinalproduct>
        <drugauthorizationnumb>21008</drugauthorizationnumb>
        <drugstructuredosagenumb>30</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>3</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>30 MG, Q3W</drugdosagetext>
        <drugadministrationroute>030</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OCTREOTIDE ACETATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SANDOSTATIN LAR DEPOT</medicinalproduct>
        <drugauthorizationnumb>21008</drugauthorizationnumb>
        <drugstructuredosagenumb>30</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>4</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>30 MG, Q4W, (EVERY 4 WEEKS)</drugdosagetext>
        <drugadministrationroute>030</drugadministrationroute>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OCTREOTIDE ACETATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SANDOSTATIN</medicinalproduct>
        <drugauthorizationnumb>21008</drugauthorizationnumb>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>UNK UNK, BID (TILL WEEK POST LAR)</drugdosagetext>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Carcinoid tumour</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20180427</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OCTREOTIDE ACETATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SANDOSTATIN</medicinalproduct>
        <drugauthorizationnumb>21008</drugauthorizationnumb>
        <drugstructuredosagenumb>30</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>4</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>30 MG, Q4W</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20180507</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OCTREOTIDE ACETATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CODEINE PHOSPHATE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Carcinoid tumour</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>CODEINE PHOSPHATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FRAGMIN</medicinalproduct>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>5000 UNK, QD</drugdosagetext>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>DALTEPARIN SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>KOMBIGLYZE XR</medicinalproduct>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>1 MG, BID</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Diabetes mellitus</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20200408</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>METFORMIN HYDROCHLORIDE\SAXAGLIPTIN HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>AMOXICILLIN\CLAVULANATE POTASSIUM</medicinalproduct>
        <drugstructuredosagenumb>875</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>875 MG, BID (FOR 10 DAYS)</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>AMOXICILLIN\CLAVULANATE POTASSIUM</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20180528</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20284609</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220103</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220103</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0269184</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Self esteem decreased</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Depression</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>General physical health deterioration</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20336354</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedate>20220114</receivedate>
    <receiptdate>20220114</receiptdate>
    <fulfillexpeditecriteria>3</fulfillexpeditecriteria>
    <authoritynumb>FDA-CDER-CTU-2022-3691</authoritynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>75</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Renal failure</reactionmeddrapt>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>AMBRISENTAN</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>FREQUENCY : DAILY;?</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Pulmonary arterial hypertension</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20180307</drugstartdate>
        <activesubstance>
          <activesubstancename>AMBRISENTAN</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20220113</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>20317512</safetyreportid>
    <primarysourcecountry>GB</primarysourcecountry>
    <occurcountry>GB</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220110</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220112</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <authoritynumb>GB-MHRA-WEBCOVID-202201051916594380-IXT9Q</authoritynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>GLAXOSMITHKLINE</duplicatesource>
      <duplicatenumb>GB-GLAXOSMITHKLINE-GBCH2022001370</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>MHRA</duplicatesource>
      <duplicatenumb>GB-MHRA-WEBCOVID-202201051916594380-IXT9Q</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>MHRA</duplicatesource>
      <duplicatenumb>GB-MHRA-ADR 26440831</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>NOVARTIS PHARMA AG</duplicatesource>
      <duplicatenumb>GB-NOVARTIS PHARMA AG-NVSC2022GB002464</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>GB</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Feeling cold</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Vaccination site pain</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Periarthritis</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>VOLTAROL</medicinalproduct>
        <drugauthorizationnumb>022122</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Blood test</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>DICLOFENAC SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MODERNA COVID-19 VACCINE</medicinalproduct>
        <drugbatchnumb>3004737</drugbatchnumb>
        <drugdosagetext>DOSE 3B</drugdosagetext>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211203</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ELASOMERAN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ASTRAZENECA COVID-19 VACCINE</medicinalproduct>
        <drugbatchnumb>Unk</drugbatchnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210320</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20210603</drugenddate>
        <drugtreatmentduration>75</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugadditional>2</drugadditional>
        <activesubstance>
          <activesubstancename>AZD-1222</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211205</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20410116</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>1</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedate>20220131</receivedate>
    <receiptdate>20220131</receiptdate>
    <fulfillexpeditecriteria>3</fulfillexpeditecriteria>
    <authoritynumb>FDA-CDER-CTU-2022-8636</authoritynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>2</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>73</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Cerebrovascular accident</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Dysphagia</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Hypotension</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pulmonary embolism</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Brain natriuretic peptide increased</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Sepsis</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Brain stem infarction</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Cerebral infarction</reactionmeddrapt>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Vertebral artery thrombosis</reactionmeddrapt>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>WARFARIN SODIUM</medicinalproduct>
        <drugindication>Atrial fibrillation</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20090707</drugstartdate>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>WARFARIN SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20220108</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20296334</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220105</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220105</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-COOPERSURGICAL, INC.-US-2021CPS002851</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>20</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>55.329</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Device expulsion</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Abnormal uterine bleeding</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Device dislocation</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PARAGARD T 380A</medicinalproduct>
        <drugbatchnumb>519004</drugbatchnumb>
        <drugauthorizationnumb>018680</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Intrauterine device</drugdosageform>
        <drugadministrationroute>015</drugadministrationroute>
        <drugindication>Contraception</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20200817</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>202108</drugenddate>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>COPPER</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ZOLOFT</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>SERTRALINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>BUSPAR</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>BUSPIRONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ALDACTONE                          /00006201/</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20210701</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20333002</safetyreportid>
    <primarysourcecountry>FR</primarysourcecountry>
    <occurcountry>FR</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220113</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220113</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>FR-NOVARTISPH-NVSC2022FR006350</companynumb>
    <primarysource>
      <reportercountry>FR</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>86</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Osteonecrosis of jaw</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Product use in unapproved indication</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ZOMETA</medicinalproduct>
        <drugauthorizationnumb>21223</drugauthorizationnumb>
        <drugdosagetext>8 CURES EN 2018</drugdosagetext>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>Plasma cell myeloma</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2018</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ZOLEDRONIC ACID</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20190901</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20319357</safetyreportid>
    <primarysourcecountry>BR</primarysourcecountry>
    <occurcountry>BR</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220110</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220110</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>BR-ANIPHARMA-2022-BR-000004</companynumb>
    <primarysource>
      <reportercountry>BR</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Malignant neoplasm progression</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Feeling abnormal</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ATACAND</medicinalproduct>
        <drugauthorizationnumb>020838</drugauthorizationnumb>
        <drugdosagetext>8 MG UNK</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Hypertension</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202109</drugstartdate>
        <actiondrug>4</actiondrug>
        <drugrecurreadministration>2</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>CANDESARTAN CILEXETIL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TAGRISSO</medicinalproduct>
        <drugdosagetext>80 MG DAILY</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Lung neoplasm malignant</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2020</drugstartdate>
        <actiondrug>4</actiondrug>
        <drugrecurreadministration>2</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>OSIMERTINIB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>RISEDRONATE SODIUM</medicinalproduct>
        <drugdosagetext>150 MG UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211122</drugstartdate>
        <drugrecurreadministration>2</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>RISEDRONATE SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>VITAMIN E</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugrecurreadministration>2</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>.ALPHA.-TOCOPHEROL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FOLIC ACID</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugrecurreadministration>2</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>FOLIC ACID</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20210101</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20345830</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220118</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220118</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-NOVARTISTESTPH-NVSC2022US010151</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Dry eye</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Abdominal discomfort</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ENTRESTO</medicinalproduct>
        <drugauthorizationnumb>207620</drugauthorizationnumb>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>24/26 MG, BID</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Cardiac failure congestive</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>SACUBITRIL\VALSARTAN</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20316558</safetyreportid>
    <primarysourcecountry>CA</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220110</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220110</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>CA-ROCHE-2995953</companynumb>
    <primarysource>
      <reportercountry>CA</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientweight>97</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Arthralgia</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Blister</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Confusional state</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Contraindicated product administered</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug ineffective</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Dyspnoea</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Fatigue</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Folliculitis</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Gastrointestinal disorder</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Hypersensitivity</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Ill-defined disorder</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Impaired healing</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Infection</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Irritable bowel syndrome</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Joint swelling</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Lower respiratory tract infection</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Muscle injury</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Nasopharyngitis</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Peripheral swelling</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pruritus</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pyrexia</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Rash</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Sinusitis</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Sleep disorder</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Stomatitis</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Swelling</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Therapeutic product effect decreased</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Weight increased</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ACTEMRA</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugauthorizationnumb>125276</drugauthorizationnumb>
        <drugstructuredosagenumb>728</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosageform>Infusion, Solution</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>Rheumatoid arthritis</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>TOCILIZUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ACETAMINOPHEN</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ACETAMINOPHEN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CHLORHEXIDINE</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>CHLORHEXIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CIMZIA</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugdosageform>Injection, Solution</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>CERTOLIZUMAB PEGOL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ENBREL</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Rheumatoid arthritis</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ETANERCEPT</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LEFLUNOMIDE</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>LEFLUNOMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>METHOTREXATE</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugadministrationroute>037</drugadministrationroute>
        <drugindication>Rheumatoid arthritis</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>METHOTREXATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ORENCIA</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugstructuredosagenumb>18</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>Rheumatoid arthritis</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>ABATACEPT</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCODONE</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugstructuredosagenumb>728</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PERIOGARD</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>CHLORHEXIDINE GLUCONATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SIMPONI</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>GOLIMUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SULFAMETHOXAZOLE AND TRIMETHOPRIM</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>SULFAMETHOXAZOLE\TRIMETHOPRIM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ARAVA</medicinalproduct>
        <drugdosageform>Tablet</drugdosageform>
        <activesubstance>
          <activesubstancename>LEFLUNOMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CETIRIZINE</medicinalproduct>
        <drugdosageform>Tablet</drugdosageform>
        <activesubstance>
          <activesubstancename>CETIRIZINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>DESOGESTREL\ETHINYL ESTRADIOL</medicinalproduct>
        <drugdosageform>Tablet</drugdosageform>
        <activesubstance>
          <activesubstancename>DESOGESTREL\ETHINYL ESTRADIOL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>IBUPROFEN</medicinalproduct>
        <activesubstance>
          <activesubstancename>IBUPROFEN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>MARVELON</medicinalproduct>
        <drugdosageform>Tablet</drugdosageform>
        <activesubstance>
          <activesubstancename>DESOGESTREL\ETHINYL ESTRADIOL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PANTOPRAZOLE SODIUM</medicinalproduct>
        <drugdosageform>Tablet, Enteric-coated</drugdosageform>
        <activesubstance>
          <activesubstancename>PANTOPRAZOLE SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PREDNISONE</medicinalproduct>
        <activesubstance>
          <activesubstancename>PREDNISONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TYLENOL</medicinalproduct>
        <activesubstance>
          <activesubstancename>ACETAMINOPHEN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ZOPICLONE</medicinalproduct>
        <drugdosageform>Tablet</drugdosageform>
        <activesubstance>
          <activesubstancename>ZOPICLONE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20276637</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220102</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220102</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0261708</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BUTRANS</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Transdermal patch</drugdosageform>
        <drugadministrationroute>062</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>BUPRENORPHINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCODONE HYDROCHLORIDE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Capsule, hard</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20407364</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220131</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220131</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PFIZER INC-202101512801</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>64</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>89.342</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>XELJANZ XR</medicinalproduct>
        <drugauthorizationnumb>208246</drugauthorizationnumb>
        <drugstructuredosagenumb>11</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>11 MG, DAILY</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Psoriatic arthropathy</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>TOFACITINIB CITRATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>XELJANZ</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <activesubstance>
          <activesubstancename>TOFACITINIB CITRATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>MODERNA COVID-19 VACCINE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <activesubstance>
          <activesubstancename>ELASOMERAN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>AMLODIPINE BESYLATE</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>10 MG</drugdosagetext>
        <activesubstance>
          <activesubstancename>AMLODIPINE BESYLATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FERROUS SULFATE</medicinalproduct>
        <drugdosagetext>325 (65) MG</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <activesubstance>
          <activesubstancename>FERROUS SULFATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>HERBALS\TURMERIC</medicinalproduct>
        <drugstructuredosagenumb>400</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>400 MG</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <activesubstance>
          <activesubstancename>HERBALS\TURMERIC</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>VITAMIN D3</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>004</drugstructuredosageunit>
        <drugdosagetext>10 UG</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <activesubstance>
          <activesubstancename>CHOLECALCIFEROL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CELEBREX</medicinalproduct>
        <drugstructuredosagenumb>100</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>100 MG</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <activesubstance>
          <activesubstancename>CELECOXIB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ATORVASTATIN CALCIUM</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>10 MG</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <activesubstance>
          <activesubstancename>ATORVASTATIN CALCIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LAMICTAL</medicinalproduct>
        <drugstructuredosagenumb>150</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>150 MG</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <activesubstance>
          <activesubstancename>LAMOTRIGINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LEVOTHYROXINE</medicinalproduct>
        <drugstructuredosagenumb>100</drugstructuredosagenumb>
        <drugstructuredosageunit>004</drugstructuredosageunit>
        <drugdosagetext>100 UG</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <activesubstance>
          <activesubstancename>LEVOTHYROXINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>BUPROPION HYDROCHLORIDE</medicinalproduct>
        <drugstructuredosagenumb>100</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>100 MG</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <activesubstance>
          <activesubstancename>BUPROPION HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>18509506</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20201117</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220111</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-ELI_LILLY_AND_COMPANY-US202010008808</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Blood glucose increased</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Hypoacusis</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Weight decreased</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Visual impairment</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug ineffective</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Accidental underdose</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TRULICITY</medicinalproduct>
        <drugbatchnumb>D233371C</drugbatchnumb>
        <drugauthorizationnumb>125469</drugauthorizationnumb>
        <drugstructuredosagenumb>1.5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>1.5 MG, UNKNOWN</drugdosagetext>
        <drugdosageform>Solution for injection in pre-filled pen</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Type 2 diabetes mellitus</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2019</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>DULAGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20303099</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220106</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220106</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-APOTEX-2022AP000093</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>APOTEX</duplicatesource>
      <duplicatenumb>US-APOTEX-2022AP000014</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
      <literaturereference>Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Bronstein AC, Rivers LJ, Pham NPT, Weber J. 2020 Annual Report of the American Association of Poison Control Centers^ National Poison Data System (NPDS): 38th Annual Report. Clinical Toxicology. 2021;59 (12):1282?1501</literaturereference>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>18</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug abuse</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>FENTANYL</medicinalproduct>
        <drugauthorizationnumb>077449</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>FENTANYL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CANNABIS SATIVA SUBSP. INDICA TOP</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>CANNABIS SATIVA SUBSP. INDICA TOP</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>20261003</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211230</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220117</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-ELI_LILLY_AND_COMPANY-US202112012873</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Injection site haemorrhage</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Injection site injury</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TRULICITY</medicinalproduct>
        <drugbatchnumb>D452226A</drugbatchnumb>
        <drugauthorizationnumb>125469</drugauthorizationnumb>
        <drugstructuredosagenumb>.75</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>0.75 MG, UNKNOWN</drugdosagetext>
        <drugdosageform>Solution for injection in pre-filled pen</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>DULAGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>20330449</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220113</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220119</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-HETERO-HET2022US00028</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Hyperkalaemia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Gastrointestinal disorder</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Abdominal distension</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LOSARTAN</medicinalproduct>
        <drugauthorizationnumb>203835</drugauthorizationnumb>
        <drugdosagetext>25 MG, ONCE IN A DAY</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Hypertension</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202105</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>202107</drugenddate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>LOSARTAN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>NAPROXEN SODIUM</medicinalproduct>
        <drugdosagetext>UNK UNK, QD</drugdosagetext>
        <drugdosageform>Pill (Except Tablets)</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Pain</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>NAPROXEN SODIUM</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20290092</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220104</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220104</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-MYLANLABS-2021M1097997</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>MLMSERVICE</duplicatesource>
      <duplicatenumb>MLMSERVICE</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>Adis</duplicatesource>
      <duplicatenumb>NZ-Adis-3624287-282718</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
      <literaturereference>Kahr PC, Moffett BS, Miyake CY, Kim JJ, Valdes SO. ^Second line medications^ for supraventricular arrhythmias in children: In-hospital efficacy and adverse events during treatment initiation of sotalol and flecainide. J-Cardiovasc-Electrophysiol 2021;32(8):2207-2215.</literaturereference>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>17</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug ineffective</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Off label use</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PROPRANOLOL</medicinalproduct>
        <drugauthorizationnumb>070213</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Atrial fibrillation</drugindication>
        <actiondrug>1</actiondrug>
        <activesubstance>
          <activesubstancename>PROPRANOLOL HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>PROPRANOLOL</medicinalproduct>
        <drugauthorizationnumb>070213</drugauthorizationnumb>
        <drugindication>Atrial flutter</drugindication>
        <actiondrug>1</actiondrug>
        <activesubstance>
          <activesubstancename>PROPRANOLOL HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SOTALOL</medicinalproduct>
        <drugauthorizationnumb>075237</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Atrial fibrillation</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>SOTALOL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SOTALOL</medicinalproduct>
        <drugauthorizationnumb>075237</drugauthorizationnumb>
        <drugindication>Atrial flutter</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>SOTALOL</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>18777059</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20210122</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220114</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-REGENERON PHARMACEUTICALS, INC.-2021-13694</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>2</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>87</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Glossodynia</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Lip pain</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Chest pain</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Chills</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Hypoxia</reactionmeddrapt>
        <reactionoutcome>2</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CASIRIVIMAB\IMDEVIMAB</medicinalproduct>
        <drugauthorizationnumb>000091</drugauthorizationnumb>
        <drugstructuredosagenumb>2.4</drugstructuredosagenumb>
        <drugstructuredosageunit>002</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugcumulativedosagenumb>2</drugcumulativedosagenumb>
        <drugcumulativedosageunit>002</drugcumulativedosageunit>
        <drugdosagetext>2.4 G, SINGLE</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>COVID-19</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20200104</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20200104</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>CASIRIVIMAB\IMDEVIMAB</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20210104</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20308757</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220107</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220107</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-NOVARTISTESTPH-NVSC2022US002829</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Fatigue</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>GLEEVEC</medicinalproduct>
        <drugbatchnumb>UNK</drugbatchnumb>
        <drugauthorizationnumb>21588</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>IMATINIB MESYLATE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20269214</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220101</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220101</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-AUROBINDO-AUR-APL-2021-052890</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
      <literaturereference>Nasrullah A, Patel S, Ud Din MT, Javed A, Arshad H, Raja A, et al.. A case of acquired immunodeficiency syndrome-related Kaposi sarcoma in a patient with COVID-19 - A brief review of HIV-COVID Co-infection and its Therapeutic challenges!. Respiratory Medicine Case Reports. 2021;34:1-4</literaturereference>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>37</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Kaposi^s sarcoma</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Human herpesvirus 8 infection</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Condition aggravated</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Off label use</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DEXAMETHASONE</medicinalproduct>
        <drugauthorizationnumb>206781</drugauthorizationnumb>
        <drugstructuredosagenumb>6</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>6 MILLIGRAM, ONCE A DAY</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>COVID-19 pneumonia</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>DEXAMETHASONE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>AMPICILLIN SODIUM\SULBACTAM SODIUM</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Antibiotic prophylaxis</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>AMPICILLIN SODIUM\SULBACTAM SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>BICTEGRAVIR SODIUM\EMTRICITABINE\TENOFOVIR ALAFENAMIDE FUMARATE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Antiretroviral therapy</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>BICTEGRAVIR SODIUM\EMTRICITABINE\TENOFOVIR ALAFENAMIDE FUMARATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FLUCONAZOLE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Oesophagitis</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>FLUCONAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>OXYGEN</medicinalproduct>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>011</drugstructuredosageunit>
        <drugdosagetext>5 LITER</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Hypoxia</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYGEN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>REMDESIVIR</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>COVID-19 pneumonia</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>REMDESIVIR</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>SULFAMETHOXAZOLE;TRIMIPRAMINE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Pneumocystis jirovecii pneumonia</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20376218</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedate>20220125</receivedate>
    <receiptdate>20220125</receiptdate>
    <fulfillexpeditecriteria>3</fulfillexpeditecriteria>
    <authoritynumb>FDA-CDER-CTU-2022-6772</authoritynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>63</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Cholecystectomy</reactionmeddrapt>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TALTZ</medicinalproduct>
        <drugstructuredosagenumb>80</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>OTHER FREQUENCY : EVERY 4 WEEKS;?</drugdosagetext>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Psoriasis</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201906</drugstartdate>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>IXEKIZUMAB</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>20337160</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220114</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220117</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-SANOFI-00912340</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>PORTAL ID</duplicatesource>
      <duplicatenumb>SanofiPVPortal20220104000940</duplicatenumb>
    </reportduplicate>
    <reportduplicate>
      <duplicatesource>SANOFI</duplicatesource>
      <duplicatenumb>US-SANOFI-00912340</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>31</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientagegroup>5</patientagegroup>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Injection site pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Injection site swelling</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DUPIXENT</medicinalproduct>
        <drugbatchnumb>0F011A</drugbatchnumb>
        <drugauthorizationnumb>761055</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>DUPILUMAB</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20387566</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220127</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220127</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-ALLERGAN-2103614US</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug ineffective</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BOTOX COSMETIC</medicinalproduct>
        <drugauthorizationnumb>1145103000</drugauthorizationnumb>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>UNK, SINGLE</drugdosagetext>
        <drugdosageform>Powder for injection</drugdosageform>
        <drugindication>Skin wrinkling</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ONABOTULINUMTOXINA</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20288210</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>1</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220104</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220104</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0266816</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HYSINGLA ER</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>HYDROCODONE BITARTRATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MS CONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MORPHINE SULFATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HYDROCODONE BITARTRATE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>HYDROCODONE BITARTRATE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20323171</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220111</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220111</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-NOVOPROD-834117</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>60</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Thyroid cyst</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Limb discomfort</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Discomfort</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Discomfort</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Dyspnoea</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Anxiety</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Vomiting</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RYBELSUS</medicinalproduct>
        <drugauthorizationnumb>213051</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202101</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2021</drugenddate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>SEMAGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RYBELSUS</medicinalproduct>
        <drugauthorizationnumb>213051</drugauthorizationnumb>
        <drugstructuredosagenumb>14</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>14 MG</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2021</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20210612</drugenddate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>SEMAGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RYBELSUS</medicinalproduct>
        <drugauthorizationnumb>213051</drugauthorizationnumb>
        <drugstructuredosagenumb>7</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>7 MG</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2021</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2021</drugenddate>
        <actiondrug>1</actiondrug>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>SEMAGLUTIDE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20210101</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20306228</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220106</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220106</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-NOVARTISPH-NVSC2022US001972</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>COVID-19</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Weight decreased</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ENTRESTO</medicinalproduct>
        <drugauthorizationnumb>207620</drugauthorizationnumb>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>UNK UNK, BID</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>SACUBITRIL\VALSARTAN</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20367357</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220124</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220124</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-JNJFOC-20220134492</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Angioedema</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>STELARA</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugauthorizationnumb>761044</drugauthorizationnumb>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Inflammatory bowel disease</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>USTEKINUMAB</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>4</safetyreportversion>
    <safetyreportid>18002435</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20200709</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220105</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-GILEAD-2020-0476593</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>46</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientagegroup>5</patientagegroup>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Renal injury</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Osteoporosis</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Chronic kidney disease</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Multiple fractures</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Osteonecrosis</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Renal failure</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Skeletal injury</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Bone loss</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Bone density decreased</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Tooth loss</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>VIREAD</medicinalproduct>
        <drugauthorizationnumb>021356</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>HIV infection</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2009</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2012</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>TENOFOVIR DISOPROXIL FUMARATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>VIREAD</medicinalproduct>
        <drugauthorizationnumb>021356</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2009</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2011</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>TENOFOVIR DISOPROXIL FUMARATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TRUVADA</medicinalproduct>
        <drugauthorizationnumb>76574</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>HIV infection</drugindication>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2009</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2016</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>TRUVADA</medicinalproduct>
        <drugauthorizationnumb>76574</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>602</drugstartdateformat>
        <drugstartdate>2010</drugstartdate>
        <drugenddateformat>602</drugenddateformat>
        <drugenddate>2016</drugenddate>
        <actiondrug>5</actiondrug>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>DESCOVY</medicinalproduct>
        <drugdosageform>Tablet</drugdosageform>
        <drugindication>HIV infection</drugindication>
        <activesubstance>
          <activesubstancename>EMTRICITABINE\TENOFOVIR ALAFENAMIDE FUMARATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>SYMTUZA</medicinalproduct>
        <activesubstance>
          <activesubstancename>COBICISTAT\DARUNAVIR\EMTRICITABINE\TENOFOVIR ALAFENAMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20100301</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20293285</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220104</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220104</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0249420</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HYDROCODONE BITARTRATE</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>HYDROCODONE BITARTRATE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>20237062</safetyreportid>
    <primarysourcecountry>JP</primarysourcecountry>
    <occurcountry>JP</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20211228</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220122</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>JP-CHUGAI-2021033294</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>CHUGAI</duplicatesource>
      <duplicatenumb>JP-CHUGAI-2021033294</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>JP</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Colon cancer</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>POLIVY</medicinalproduct>
        <drugbatchnumb>ASKED BUT UNKNOWN</drugbatchnumb>
        <drugauthorizationnumb>761121</drugauthorizationnumb>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>041</drugadministrationroute>
        <drugindication>Diffuse large B-cell lymphoma</drugindication>
        <actiondrug>1</actiondrug>
        <activesubstance>
          <activesubstancename>POLATUZUMAB VEDOTIN-PIIQ</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20395049</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220130</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220130</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-JNJFOC-20220140620</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Raynaud^s phenomenon</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>STELARA</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugauthorizationnumb>125261</drugauthorizationnumb>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>USTEKINUMAB</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>2</safetyreportversion>
    <safetyreportid>20288680</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>3</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220104</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220113</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-NEUROCRINE BIOSCIENCES INC.-2021NBI07547</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Tardive dyskinesia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Constipation</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug ineffective</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>INGREZZA</medicinalproduct>
        <drugbatchnumb>2100127, 2100124</drugbatchnumb>
        <drugauthorizationnumb>209241</drugauthorizationnumb>
        <drugstructuredosagenumb>80</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext>80 MILLIGRAM, QD</drugdosagetext>
        <drugdosageform>Capsule</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Tardive dyskinesia</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20211201</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20220105</drugenddate>
        <drugtreatmentduration>36</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>VALBENAZINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TIZANIDINE</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <activesubstance>
          <activesubstancename>TIZANIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TRAMADOL</medicinalproduct>
        <drugdosagetext>UNK</drugdosagetext>
        <activesubstance>
          <activesubstancename>TRAMADOL</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20211201</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20378378</safetyreportid>
    <occurcountry>KR</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>1</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220126</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220126</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>KR-Acacia Pharma Limited-2124291</companynumb>
    <primarysource>
      <reportercountry>KR</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>23</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Anaphylactic reaction</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Electrocardiogram ST segment depression</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Administration site oedema</reactionmeddrapt>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>BYFAVO</medicinalproduct>
        <drugauthorizationnumb>212295</drugauthorizationnumb>
        <drugstructuredosagenumb>12</drugstructuredosagenumb>
        <drugstructuredosageunit>007</drugstructuredosageunit>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>805</drugintervaldosagedefinition>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>042</drugadministrationroute>
        <drugindication>Induction of anaesthesia</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20220110</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20220110</drugenddate>
        <drugtreatmentduration>2</drugtreatmentduration>
        <drugtreatmentdurationunit>806</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>1</drugadditional>
        <activesubstance>
          <activesubstancename>REMIMAZOLAM BESYLATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>MIDAZOLAM</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20220110</drugstartdate>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>MIDAZOLAM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PHENIRAMINE</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20220110</drugstartdate>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>PHENIRAMINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>PHENYLEPHRINE</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20220110</drugstartdate>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>PHENYLEPHRINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>EPINEPHRINE</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>004</drugstructuredosageunit>
        <drugadministrationroute>065</drugadministrationroute>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20220110</drugstartdate>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>EPINEPHRINE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20220110</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20403883</safetyreportid>
    <primarysourcecountry>GR</primarysourcecountry>
    <occurcountry>GR</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220131</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220131</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>GR-ABBVIE-22K-066-4252648-00</companynumb>
    <primarysource>
      <reportercountry>COUNTRY NOT SPECIFIED</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>81</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>62</patientweight>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Respiratory tract infection</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Productive cough</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Dyspnoea</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Dysphagia</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CARBIDOPA\LEVODOPA</medicinalproduct>
        <drugbatchnumb>21I03G08A</drugbatchnumb>
        <drugauthorizationnumb>203952</drugauthorizationnumb>
        <drugdosagetext>MORNING DOSE: 11.0ML; CONTINUOUS RATE: 4.8ML/H; EXTRA DOSE: 2.0ML</drugdosagetext>
        <drugdosageform>Intestinal gel</drugdosageform>
        <drugadministrationroute>050</drugadministrationroute>
        <drugindication>Parkinson^s disease</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20171121</drugstartdate>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>CARBIDOPA\LEVODOPA</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>CARBIDOPA\LEVODOPA</medicinalproduct>
        <drugbatchnumb>21I03G08A</drugbatchnumb>
        <drugauthorizationnumb>203952</drugauthorizationnumb>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>CARBIDOPA\LEVODOPA</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>BENSERAZIDE HYDROCHLORIDE\LEVODOPA</medicinalproduct>
        <drugseparatedosagenumb>6</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>(200 + 50)MG</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Parkinson^s disease</drugindication>
        <activesubstance>
          <activesubstancename>BENSERAZIDE HYDROCHLORIDE\LEVODOPA</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>EXELON</medicinalproduct>
        <drugdosagetext>13.3MG</drugdosagetext>
        <drugadministrationroute>062</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>RIVASTIGMINE TARTRATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>BROMAZEPAM</medicinalproduct>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>UNIT DOSE: 1.5MG / FORM STRENGTH: 3MG</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>BROMAZEPAM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>CLONAZEPAM</medicinalproduct>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>UNIT DOSE: 0.5MG / FORM STRENGTH: 2MG</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>CLONAZEPAM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>QUETIAPINE</medicinalproduct>
        <drugseparatedosagenumb>3</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>QUETIAPINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>RABEPRAZOLE SODIUM</medicinalproduct>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>RABEPRAZOLE SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FOLIC ACID</medicinalproduct>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>FOLIC ACID</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>NEUROBION</medicinalproduct>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>802</drugintervaldosagedefinition>
        <drugadministrationroute>050</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>CYANOCOBALAMIN\PYRIDOXINE\THIAMINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>SEROQUEL</medicinalproduct>
        <drugstructuredosagenumb>75</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>3</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>QUETIAPINE FUMARATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TAMSULOSIN HYDROCHLORIDE</medicinalproduct>
        <drugdosagetext>0.4MG</drugdosagetext>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>TAMSULOSIN HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>QUETIAPINE</medicinalproduct>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>QUETIAPINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>MONTELUKAST SODIUM</medicinalproduct>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <activesubstance>
          <activesubstancename>MONTELUKAST SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20220101</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20324964</safetyreportid>
    <primarysourcecountry>JP</primarysourcecountry>
    <occurcountry>JP</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220111</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220111</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>JP-JNJFOC-20220111754</companynumb>
    <primarysource>
      <reportercountry>JP</reportercountry>
      <qualification>2</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>54</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientagegroup>5</patientagegroup>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Trigger finger</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>SIMPONI</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugauthorizationnumb>125289</drugauthorizationnumb>
        <drugstructuredosagenumb>100</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>4</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosageform>Solution for injection in pre-filled pen</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Colitis ulcerative</drugindication>
        <actiondrug>1</actiondrug>
        <activesubstance>
          <activesubstancename>GOLIMUMAB</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
</ichicsr>
